使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings, and welcome to the Align Technology Q4 Full Year Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to Shirley Stacy with Align. Thank you. Please begin.
各位好,歡迎參加 Align Technology 第四季暨全年財報電話會議。(接線員指示) 提醒各位,本次會議將被錄音。現在我想把會議交給 Align 的 Shirley Stacy。謝謝。請開始。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO. We issued fourth quarter and full year 2018 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com.
各位午安,感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同出席電話會議的有總裁兼執行長 Joe Hogan,以及財務長 John Morici。我們今天已透過 GlobeNewswire 發布 2018 年第四季與全年財務結果,相關資訊可於我們網站 investor.aligntech.com 取得。
Today's conference call is also being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 p.m. Eastern time through 5:30 p.m. Eastern time on February 12.
今天的電話會議也將以音訊方式進行網路直播,並將在我們網站上存檔約 12 個月。電話重播預計將於今日約東部時間下午 5:30 提供。東部時間並持續至 2 月 12 日東部時間下午 5:30。
To access the telephone replay, domestic callers should dial (877) 660-6853 with conference number 13685779 followed by #. International callers should dial (201) 612-7415, with the same conference number.
如需收聽電話重播,美國境內來電者請撥打 (877) 660-6853,輸入會議編號 13685779 後按 #。國際來電者請撥打 (201) 612-7415,會議編號相同。
As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook and the expected financial results for the first quarter and full year outlook for 2019. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statement. We have posted historical financial statements, including the corresponding reconciliations and our fourth quarter and full year 2018 conference call slides on our website, under Quarterly Results. Please refer to these files for more detailed information.
提醒各位,簡報者今天討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2019 年第一季預期財務結果與 2019 年全年展望的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們最近向美國證券交易委員會提交的定期報告中更詳細說明。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述的義務。我們已在網站「季度業績」(Quarterly Results) 欄目下發布歷史財務報表(含相應調節表)以及 2018 年第四季與全年電話會議簡報投影片。如需更詳細資訊,請參閱上述檔案。
With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我將把電話會議交給 Align Technology 總裁兼執行長 Joe Hogan。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide some highlights in the fourth quarter and the full year, then briefly discuss the performance of our 2 operating segments: Clear aligners and intraoral scanners. John will provide more detail on our financial results, discuss our outlook for the first quarter and share our thoughts for 2019. Following that, I'll come back and summarize a few key points and open up the call to questions.
謝謝你,Shirley。各位午安,感謝各位加入我們。在今天的電話會議中,我將先提供第四季與全年的一些重點,接著簡要說明我們兩個營運部門的表現:透明牙套與口內掃描儀。John 將更詳細說明我們的財務結果,討論第一季展望,並分享我們對 2019 年的看法。之後我會回來總結幾個重點,並開放提問。
Our fourth quarter was a strong finish to a great year. Q4 revenues were better than expected, reflecting higher Invisalign ASPs and volume growth of 31% year-over-year. As well as another record quarter for iTero scanners with revenue up 55% year-over-year. Q4 sequential growth was driven by a strong quarter for EMEA with record growth for teens as well as continued traction with Invisalign Lite and iGo. Q4 operating margin of 22.6% reflects higher doctor training and manufacturing costs as well as higher legal fees than anticipated, partially offset by sequential improvement in Invisalign ASPs. For the quarter, we trained a record 5,270 new doctors in Q4, which includes about 3,000 international doctors, of which, half were in EMEA and half were in APAC.
我們第四季為這個精彩的一年畫下強勁句點。第四季營收優於預期,反映 Invisalign 平均銷售單價(ASP)較高,以及病例量年增 31%。同時 iTero 掃描儀也再創單季新高,營收年增 55%。第四季的季增成長主要由 EMEA 的強勁表現帶動,青少年業務創下成長新高,Invisalign Lite 與 iGo 也持續獲得市場動能。第四季營業利益率為 22.6%,反映醫師培訓與製造成本上升,以及法律費用高於預期;部分被 Invisalign ASP 的季增改善所抵銷。本季我們培訓了創紀錄的 5,270 位新醫師,其中約 3,000 位為國際醫師;其中一半在 EMEA,另一半在 APAC。
For the year, we achieved record revenues of nearly $2 billion and had over 1.2 million people start treatment with Invisalign clear aligners for the first time, resulting in our 6 millionth Invisalign patient, a teenager from China. These results reflect record revenues and volumes for both Invisalign and iTero. Across customer channels and country markets and continued strength from teens, which grew 40%. The total number of teenagers treated with Invisalign this year was over 333,000, representing 27% of our volume. Finally, in 2018, we trained a record number of new Invisalign doctors, nearly 20,000 worldwide. And for the first time, more than half of them were international doctors.
就全年而言,我們達成接近 20 億美元的創紀錄營收,並有超過 120 萬人首次開始使用 Invisalign 透明牙套治療,使我們迎來第 600 萬位 Invisalign 病患——一位來自中國的青少年。這些成果反映 Invisalign 與 iTero 皆創下營收與出貨量新高。涵蓋各客戶通路與各國市場,且青少年業務持續強勁,年增 40%。今年接受 Invisalign 治療的青少年總數超過 333,000 人,占我們總量的 27%。最後,2018 年我們在全球培訓了創紀錄數量的新 Invisalign 醫師,接近 20,000 位。且首次有超過一半為國際醫師。
Now let's turn to the specifics around our fourth quarter results starting with the Americas region.
接下來我們來看第四季業績的細節,先從美洲地區開始。
For the Americas region, Q4 Invisalign case volume increased 21.7% year-over-year and was down sequentially off a record Q3 volumes, which benefited from strong uptake of promotions last quarter, predominantly by high-volume Invisalign doctors. On a sequential basis, Q4 reflects growth from the Americas GPs, offset by America's orthos, particularly high-volume doctors. Year-over-year growth for Q4 reflects continued adoption of Invisalign treatment from both orthodontist and GP channels, which were up 24.7% and 17.3%, respectively. We also saw good growth from our DSO partners across both GPs and orthos, up nearly 50% year-over-year.
在美洲地區,第四季 Invisalign 病例量年增 21.7%,但較前一季下滑,因第三季創下歷史新高的出貨量,受惠於上季促銷活動的強勁採用,且主要來自高量 Invisalign 醫師。以季比來看,第四季反映美洲一般牙醫(GP)成長,但被美洲矯正專科(ortho)所抵銷,尤其是高量醫師。以年比來看,第四季成長反映矯正專科與一般牙醫兩個通路對 Invisalign 治療的持續採用,分別年增 24.7% 與 17.3%。我們也看到 DSO 合作夥伴在一般牙醫與矯正專科兩端皆有良好成長,年增接近 50%。
For the full year, Invisalign volume for the Americas region was up 24.2% compared to 2017. Americas orthos were up 27.2% and Americas GP dentists were up 19.8%, the second highest annual growth rate for orthos and the highest annual growth rate for GPs in 6 years.
就全年而言,美洲地區 Invisalign 出貨量較 2017 年成長 24.2%。美洲矯正專科成長 27.2%,美洲一般牙醫成長 19.8%;這是矯正專科第二高的年度成長率,也是一般牙醫 6 年來最高的年度成長率。
For Q4, we trained a record 2,290 new Invisalign doctors in the Americas region, of which, 1,725 were North American doctors and 565 were Latin American doctors. In total, we trained 7,885 new Invisalign doctors in the Americas in 2018, an increase of 19%.
第四季我們在美洲地區培訓了創紀錄的 2,290 位新 Invisalign 醫師,其中 1,725 位為北美醫師,565 位為拉丁美洲醫師。2018 年我們在美洲合計培訓 7,885 位新 Invisalign 醫師,增加 19%。
For our international business, Q4 was a great quarter with Invisalign case volume up 12.2% sequentially, driven by strong growth in the EMEA region, offset somewhat by seasonality in the Asia Pacific region. On a year-over-year basis, strong Invisalign volume growth of 45.3% reflects increased utilization and continued expansion of our customer base in both EMEA and the Asia Pacific region. In Q4, we trained nearly 3,000 new Invisalign doctors internationally with roughly 50% in EMEA and 50% in APAC.
在國際業務方面,第四季表現出色,Invisalign 病例量季增 12.2%,主要由 EMEA 地區的強勁成長帶動,但部分被亞太地區的季節性因素所抵銷。以年比來看,Invisalign 出貨量強勁成長 45.3%,反映 EMEA 與亞太地區的使用率提升,以及客戶基礎持續擴張。第四季我們在國際市場培訓了近 3,000 位新 Invisalign 醫師,其中約 50% 在 EMEA、50% 在 APAC。
In EMEA, Q4 was a strong quarter, up 42.7% year-over-year, driven by record Invisalign volumes in all country markets as well as strong growth in the teen segment, which is up 75.1% from the prior year, reflecting continued success of our Teen 360 program. For the full year, EMEA was up 38.6% led by Iberia, France and the U.K. as well as our key expansion markets led by Central and Eastern Europe. During 2018, we went direct in Turkey, Israel and Russia, adding to our expansion country markets.
在 EMEA,第四季表現強勁,年增 42.7%,主要由所有國家市場的 Invisalign 出貨量創新高所帶動,同時青少年業務也強勁成長,較去年同期增加 75.1%,反映我們 Teen 360 計畫的持續成功。就全年而言,EMEA 成長 38.6%,由伊比利亞、法國與英國領軍,並由中東歐帶動的關鍵擴張市場共同推升。2018 年期間,我們在土耳其、以色列與俄羅斯改採直營,進一步擴大我們的擴張國家市場。
For APAC, Q4 was down sequentially as expected due to seasonality -- seasonally slower period in the region, up 49.3% year-over-year with record Invisalign volume in almost every country market led by China, Japan, ANZ. Q4 results reflect continued strong growth from teenage patients as well as adults, with GP dentists up 77.1% year-over-year.
就亞太地區(APAC)而言,第四季如預期因季節性因素而較前一季下滑——該區域屬於季節性較淡的期間;但年增49.3%,幾乎每個國家市場的 Invisalign 出貨量皆創新高,其中以中國、日本、澳紐(ANZ)領先。第四季業績反映青少年患者與成人患者持續強勁成長,同時全科牙醫(GP)年增77.1%。
During Q4, we trained 1,530 new doctors in APAC, of which half were in China. We held several clinical education events across APAC designed to help increase doctor's confidence in adoption in Invisalign treatment, including how critical the iTero scanner is to practice growth.
第四季期間,我們在亞太地區培訓了1,530位新醫師,其中一半在中國。我們在亞太各地舉辦多場臨床教育活動,旨在提升醫師採用 Invisalign 治療的信心,包括說明 iTero 掃描儀對診所成長有多關鍵。
For the year, Invisalign volume from the international doctors increased 45% led by growth from China and our core EMEA country markets. In total, international volumes represented 41% of worldwide Invisalign case shipments.
就全年而言,國際醫師的 Invisalign 出貨量成長45%,主要由中國以及我們核心的歐洲、中東與非洲(EMEA)國家市場的成長帶動。整體來看,國際出貨量占全球 Invisalign 病例出貨量的41%。
Despite our record results, we're still very clearly underpenetrated in APAC overall and specifically in China. As the second largest market for Align, China represents enormous growth potential, and our ability to expand and drive penetration across the region relies on our ability to be closer to doctors and their patients, communicate in local language and as much as possible, operate like a local company.
儘管我們創下紀錄的業績表現,但在亞太整體、尤其在中國,我們的滲透率仍明顯偏低。作為 Align 的第二大市場,中國具備龐大的成長潛力;而我們能否在區域內擴張並提升滲透率,取決於我們能否更貼近醫師及其患者、以當地語言溝通,並在可行範圍內以在地公司的方式營運。
Late in Q4, we began fabricating Invisalign aligners in our new manufacturing facility in Ziyang, China, our first aligner fabrication facility outside of Juarez, Mexico. There's a temporary facility that will be replaced by our own building in 2020. Over the next year, we will continue to build our manufacturing capabilities in Ziyang and ramp up production to serve the rapidly growing Chinese market. However, it would take a couple of quarters to fully transition aligner production from Juarez to Ziyang, and we would expect manufacturing overhead in Ziyang to be underutilized during this period.
在第四季末,我們開始在中國資陽(Ziyang)的新製造設施生產 Invisalign 隱形牙套,這是我們在墨西哥華雷斯(Juarez)之外的第一座牙套製造工廠。目前有一座臨時設施,將於2020年由我們自有的新建廠房取代。在未來一年,我們將持續建置資陽的製造能力並逐步提升產能,以服務快速成長的中國市場。然而,將牙套生產從華雷斯完全轉移至資陽需要數個季度;在此期間,我們預期資陽的製造間接費用(manufacturing overhead)將出現產能利用不足的情況。
Product and technology innovation continues to be a key growth driver across our regions. Over the past year, we launched several new Invisalign offerings for both comprehensive and noncomprehensive treatment to give doctors more tools and choices to treat a greater range of cases, from adults to teenagers and now even kids as young as 7 years old.
產品與技術創新仍是我們各區域成長的關鍵驅動力。過去一年,我們針對完整療程與非完整療程推出多項新的 Invisalign 產品方案,為醫師提供更多工具與選擇,以治療更廣泛的病例範圍,從成人到青少年,現在甚至涵蓋最小7歲的兒童。
In mid-2018, we launched a new Invisalign Go product with a more user-friendly iTero digital chairside experience and greater flexibility to treat a wider range of mild to moderate cases such as crowded or gapped teeth that require teeth straightening prior to restorative treatments.
2018年年中,我們推出全新的 Invisalign Go 產品,提供更友善的 iTero 數位椅旁體驗,並具備更高彈性,可治療更廣泛的輕度至中度病例,例如牙齒擁擠或牙縫過大等;這些情況在進行修復性治療前往往需要先進行牙齒矯正。
We also began offering Invisalign First, designed specifically to address a broad range of younger patients' malocclusions, including shorter clinical crowns, management of erupting dentition and predictable dental arch expansion. We're pleased with the initial uptake and customer feedback. In 2018, we shipped nearly 5,000 Invisalign First cases to over 1,300 doctors, primarily in North America, EMEA, Australia, New Zealand, and Japan.
我們也開始提供 Invisalign First,專為解決較年幼患者的多種咬合不正而設計,包括較短的臨床牙冠、萌出期牙列的管理,以及可預期的牙弓擴張。我們對初期採用情況與客戶回饋感到滿意。2018年,我們出貨近5,000例 Invisalign First 病例給超過1,300位醫師,主要分布於北美、EMEA、澳洲、紐西蘭與日本。
And in October, we received FDA approval for Invisalign with mandibular advancement feature in the U.S., which is the only clear aligner product approved to simultaneously move teeth and the mandible in young patients. In Q4, we began shipping mandibular advancement in the U.S. Late in the quarter, we are seeing initial uptake along with continued ramp globally. To date, over 17,000 teenagers have used Invisalign treatment with mandibular advancement, led by China, Canada, France and Spain.
此外,在10月,我們在美國取得具下顎前移(mandibular advancement)功能的 Invisalign 產品之 FDA 核准;這是唯一獲准可在年輕患者身上同時移動牙齒與下顎的透明牙套產品。第四季我們開始在美國出貨下顎前移產品;在季度末,我們看到初期採用情況,同時也持續在全球推進放量。截至目前,已有超過17,000名青少年使用具下顎前移功能的 Invisalign 治療,其中以中國、加拿大、法國與西班牙為主。
Overall for the teen market, in Q4, over 87,000 teenagers started treatment with Invisalign clear aligners, an increase of 37.3% year-over-year, driven by continued strong adoption across all major regions, driven by both the Americas and EMEA regions. For Q4, year-over-year Invisalign teen patient growth for North America orthos increased 23.7% and international doctors were up 63.7%. For the full year, total teen cases worldwide grew 40.3% to a total of 333,000 teenagers, or 27.1% of our total volume.
整體而言,就青少年市場來看,第四季有超過87,000名青少年開始使用 Invisalign 透明牙套治療,年增37.3%;此成長來自所有主要區域的持續強勁採用,並由美洲與 EMEA 地區帶動。第四季北美矯正專科醫師(orthos)的 Invisalign 青少年患者年增23.7%,國際醫師則年增63.7%。全年全球青少年病例總數成長40.3%至333,000名青少年,占我們總出貨量的27.1%。
Our consumer marketing efforts are designed to build the category and drive demand for Invisalign treatment through a doctor's office. We invest over $100 million each year in consumer marketing and programs, including TV, digital, social media, PR, event marketing and more recently, our patient concierge and Invisalign Experience program. Our goals are to make the Invisalign brand a household name worldwide and to motivate consumers to seek Invisalign treatment through a doctor's office.
我們的消費者行銷工作旨在擴大品類並透過醫師診所推動 Invisalign 治療需求。我們每年在消費者行銷與相關方案上投入超過1億美元,包括電視、數位、社群媒體、公關、活動行銷等,以及近期推出的患者禮賓服務(patient concierge)與 Invisalign Experience 計畫。我們的目標是讓 Invisalign 品牌在全球成為家喻戶曉的名稱,並促使消費者透過醫師診所尋求 Invisalign 治療。
In Q4, we continued to see strong digital engagement with consumers and had nearly 4 million unique visitors on invisalign.com sites for a total of 17 million over the year. Other key metrics show increased activity and engagement with the Invisalign brand and are included in our fourth quarter slides.
第四季我們持續看到消費者端強勁的數位互動,invisalign.com 各站點的獨立訪客接近400萬人次,全年合計達1,700萬人次。其他關鍵指標亦顯示 Invisalign 品牌的活動度與互動度提升,並已納入我們第四季簡報投影片中。
The impact of the digital technology on our world and specifically in our industry is challenging our customers to evolve just about every aspect of their practice, especially how they engage with consumers and turn them into patients. What worked for doctors in the past from a marketing, conversion or workflow perspective will not work today. Consumers expect more and are demanding different types of digital-driven experiences. Many doctors don't know where and how to start. The work we are doing with our integrated consumer marketing platform, patient concierge service, and Invisalign Experience program has given us better insights and information that we're sharing with doctors to help them reshape their practices.
數位科技對我們世界、尤其對本產業的影響,正迫使客戶在幾乎所有診所營運面向上進化,特別是如何與消費者互動並將其轉化為患者。過去醫師在行銷、轉換或工作流程方面有效的方法,如今已不再適用。消費者期待更多,並要求不同類型、由數位驅動的體驗。許多醫師不知道該從何處、以何種方式開始。我們透過整合式消費者行銷平台、患者禮賓服務與 Invisalign Experience 計畫所做的工作,讓我們獲得更佳洞察與資訊,並分享給醫師,協助他們重塑診所營運。
For example, the Invisalign Experience program is designed to reach consumers in a retail environment where they shop, play and dine and educate them on the benefits of Invisalign treatment and value of getting a better smile and connect them with an Invisalign doctor.
例如,Invisalign Experience 計畫旨在於消費者購物、休閒與用餐的零售環境中觸及他們,向其介紹 Invisalign 治療的優勢與擁有更美笑容的價值,並將其連結至 Invisalign 醫師。
One of the ways we do this is through the Invisalign store, which is owned and operated by Align. Invisalign stores bring the brand directly to consumers in a contemporary, interactive digital environment. Consumers can browse, ask questions, learn about Invisalign treatment and technology, and the benefits of straightening their teeth. Visitors are offered a complimentary iTero intraoral 3D scan and a visual simulation of what their smile might look like after Invisalign treatment. Interested consumers are connected with a local Invisalign doctor's office of their choice to discuss potential treatment options.
我們達成此目標的方式之一,是透過由 Align 擁有並營運的 Invisalign 門市(Invisalign store)。Invisalign 門市在現代化、互動式的數位環境中,將品牌直接帶到消費者面前。消費者可瀏覽、提問、了解 Invisalign 治療與技術,以及矯正牙齒的益處。訪客可獲得免費的 iTero 口內3D掃描,以及 Invisalign 治療後笑容可能樣貌的視覺化模擬。有興趣的消費者可依其選擇,與當地的 Invisalign 醫師診所建立連結,以討論可能的治療選項。
By the end of 2018, we finished with 12 locations in the United States, and these stores are helping us learn more than ever about reducing barriers to treatment for potential patients so that they are excited about getting a better smile with an Invisalign doctor. In addition to providing potential leads to participating Invisalign practices, we're also seeing a positive halo effect and increased growth rates for all of the Invisalign practices in the surrounding area, whether they participate in the store network or not.
截至2018年底,我們在美國共有12個據點;這些門市正協助我們以前所未有的程度了解如何降低潛在患者接受治療的門檻,讓他們對透過 Invisalign 醫師獲得更美笑容感到期待。除了為參與的 Invisalign 診所提供潛在客源外,我們也看到正向的光環效應(halo effect),以及周邊所有 Invisalign 診所(不論是否加入門市網絡)皆出現更高的成長率。
Over the past year, more than 55,000 consumers visited Invisalign store and nearly 10,000 received a complimentary scan. While we are still early in the development of our Invisalign stores and the overarching Invisalign Experience program, we're excited about its potential and the positive impact we can have on demand creation for Invisalign practices by engaging directly with consumers.
在過去一年中,超過55,000名消費者造訪Invisalign門市,近10,000人接受了免費掃描。雖然我們在Invisalign門市以及整體Invisalign Experience計畫的發展上仍處於早期階段,但我們對其潛力以及透過直接與消費者互動、為Invisalign診所創造需求所能帶來的正面影響感到振奮。
The Invisalign Experience program is just getting started and continues to evolve. In October, we announced that we were partnering with a few Invisalign doctors in selected U.S. cities to pilot new ways to reach consumers and connect them directly with doctors to start Invisalign treatment. These Invisalign Experience locations are owned and operated by doctors under a special license from Align and are intended to help doctors integrate consumer friendly design and consultation workflow into their practices and test new Invisalign Experience branding and explore a consumer focused approach to consultations and Invisalign treatments starts in a variety of settings, including in-office, retail and mobile. We'll continue to share our learnings as we get more of these pilots up and running.
Invisalign Experience計畫才剛起步,並持續演進。10月,我們宣布與美國部分城市的幾位Invisalign醫師合作,試行新的方式來觸及消費者,並將他們直接連結到醫師以開始Invisalign療程。這些Invisalign Experience據點由醫師在Align的特殊授權下擁有並營運,旨在協助醫師將以消費者為友善的設計與諮詢工作流程整合進其診所,並測試新的Invisalign Experience品牌,同時探索以消費者為中心的諮詢方式,以及在多種場景中啟動Invisalign療程(包括診所內、零售與行動式)。隨著我們讓更多試點據點上線並運作,我們將持續分享所學。
Finally, I want to spend a few minutes talking about digital technology and the transformation in our industry from an old analog process to an end-to-end digital workflow. Align is helping doctors on their digital journey, which starts with an iTero scanner and ends with stronger practices and better smiles for their patients. As a leader in digital orthodontics, we are best positioned to help Invisalign-trained doctors find more efficient ways to drive digitalization in their practices and support those practices and to help them improve their productivity over time.
最後,我想花幾分鐘談談數位科技,以及我們產業從傳統類比流程轉型為端到端數位工作流程的變革。Align正在協助醫師踏上數位化旅程,這段旅程從iTero掃描儀開始,最終帶來更強健的診所經營與患者更美好的笑容。作為數位齒顎矯正的領導者,我們最有能力協助受過Invisalign訓練的醫師,找到更有效率的方法推動其診所的數位化並提供支援,並協助他們隨時間提升生產力。
To that end, last year, we launched project [PNO] we now call -- we have renamed it ADAPT, Align digital and practice transformation, with several small orthodontic clinics across EMEA, APAC and North America with the objective to demonstrate that a fully digital practice can be productive, efficient and profitable.
為此,去年我們啟動了專案[PNO],現已重新命名為ADAPT(Align數位與診所轉型),並在EMEA、APAC與北美的數家小型齒顎矯正診所推行,目標是證明全數位化診所可以兼具生產力、效率與獲利能力。
Process involves detailed analysis of the current practice of data and workflows performed by experts and continuous improvement in workflow. While it's still early, the initial results from the ADAPT study are incredibly promising. Based upon the study on practice development, we've come to the conclusion that to benefit fully from technology and to own the digital transformation of their practices, doctors need to organize their workflows and premises so that approximately 80% of their organization is built around this digital transformation with clear aligners. This means that doctors who commit to digital transformation have the potential to do more, see more patients and expand their practice or take more time off. Whatever their goals, with Invisalign plus iTero together, we can help them see the benefits they want from a fully end-to-end digital workflow.
該流程包含由專家對目前診所資料與工作流程進行詳細分析,並持續改善工作流程。雖然仍處於早期階段,ADAPT研究的初步結果極具前景。根據對診所發展的研究,我們得出結論:若要充分受益於科技並掌握診所的數位轉型,醫師需要重新組織其工作流程與場域配置,使其組織約80%能圍繞以透明牙套為核心的數位轉型來建構。這意味著,承諾進行數位轉型的醫師有潛力做得更多、看診更多患者,並擴大其診所規模或騰出更多休假時間。無論其目標為何,透過Invisalign加上iTero的組合,我們都能協助他們從完整端到端的數位工作流程中獲得所期望的效益。
For iTero scanner and services business, Q4 was a very strong quarter with better-than-expected revenues, which were up 13% sequentially and 54.8% year-over-year, driven by strength in all regions and customer channels. Record Q4 volumes reflect continued commercialization of the iTero 2 Element and Element Flex scanners, especially for restorative GP dentists in North America, the continued rollout of our major DSO partners and increased sales internationally, including Italy, Japan and China, where we began manufacturing the iTero Element this past year. For 2018, we had an outstanding year for iTero scanners with volumes up 77.2% year-over-year. Cumulatively, over 11.5 million orthodontic scans and 3.2 million restorative scans have started with iTero scanners. Use of the iTero scanners for Invisalign case submission continues to grow and remains a positive catalyst for Invisalign utilization.
就iTero掃描儀與服務業務而言,第四季表現非常強勁,營收優於預期,較前一季成長13%,較去年同期成長54.8%,主要受所有地區與客戶通路的強勁表現帶動。第四季創紀錄的出貨量反映iTero 2 Element與Element Flex掃描儀持續商業化推廣,特別是在北美的修復科一般牙醫(GP)方面;同時也反映我們主要DSO合作夥伴的持續導入,以及國際銷售增加,包括義大利、日本與中國(我們於過去一年開始在中國製造iTero Element)。2018年對iTero掃描儀而言是非常出色的一年,出貨量較去年同期成長77.2%。累計而言,已有超過1,150萬次齒顎矯正掃描與320萬次修復掃描由iTero掃描儀啟動。使用iTero掃描儀提交Invisalign病例的比例持續成長,並仍是推動Invisalign使用量的正向催化劑。
For Q4, total Invisalign cases submitted with digital scanner in the Americas increased 72.6% from 65.3% in Q4 last year. International scans increased 57.5%, up 41.4% in the same quarter last year. What's really exciting to see is that within the Americas, 88.7% of cases submitted by North American orthos were submitted digitally. And China went from 0 to 45.9% in 1 year. This means that within 1 year or 2, nearly all Invisalign cases will be submitted digitally, primarily through an iTero scanner. We're very excited about the continued progress we've made with iTero business overall, and remain confident that we'll continue to help drive our overall growth and help increase adoption of Invisalign treatment.
第四季,美洲地區使用數位掃描儀提交的Invisalign病例占比提升至72.6%,高於去年第四季的65.3%。國際市場的數位掃描占比成長57.5%,高於去年同季的41.4%。真正令人振奮的是,在美洲地區,北美矯正科醫師提交的病例中有88.7%是以數位方式提交。而中國在一年內從0提升到45.9%。這表示在未來1到2年內,幾乎所有Invisalign病例都將以數位方式提交,主要透過iTero掃描儀完成。我們對iTero業務整體持續取得的進展感到非常振奮,並仍有信心我們將持續推動整體成長,並協助提升Invisalign療程的採用率。
With that, I'll now turn the call over to John.
接下來,我把電話交給John。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Thanks, Joe. Now for our Q4 financial results. Total revenue for the fourth quarter was $534 million, up 5.7% from the prior quarter and up 26.7% from the corresponding quarter a year ago.
謝謝,Joe。現在來看我們第四季的財務結果。第四季總營收為5.34億美元,較前一季成長5.7%,較去年同期成長26.7%。
For the full year, revenue of about $2 billion was up 33.5% year-over-year, reflecting a record 1.2 million Invisalign shipments and 31.9% year-over-year growth, with strength across all regions and customer channels as well as record iTero scanners volume, which was up 77.2%.
全年而言,營收約20億美元,較去年同期成長33.5%,反映Invisalign出貨量創紀錄達120萬件、年增31.9%,且所有地區與客戶通路皆表現強勁;同時iTero掃描儀出貨量亦創新高,年增77.2%。
For clear aligners, Q4 revenue of $445.6 million was up 4.3% sequentially on higher-than-expected Invisalign ASPs and strong Invisalign volume from EMEA. Year-over-year clear aligner revenue growth of 22.4% reflected strong Invisalign shipment across all customer channels and geographies.
就透明牙套而言,第四季營收為4.456億美元,因Invisalign平均售價(ASP)高於預期以及EMEA地區Invisalign出貨量強勁,較前一季成長4.3%。透明牙套營收年增22.4%,反映所有客戶通路與地理區域的Invisalign出貨皆強勁。
Q4 Invisalign ASPs were up sequentially by approximately $5 to $1,235, reflecting price increases and lower discounts, partially offset by higher growth on noncomprehensive cases and includes $10 of unfavorable foreign exchange. On a year-over-year basis, Q4 Invisalign ASPs were down approximately $70, reflecting promotional discounts, higher growth on noncomprehensive cases and includes $25 of unfavorable foreign exchange, partially offset by price increases.
第四季Invisalign ASP較前一季約增加5美元至1,235美元,反映價格上調與折扣降低,但部分被非全療程(noncomprehensive)病例較高的成長所抵銷,並包含10美元的不利匯率影響。以年對年來看,第四季Invisalign ASP約下降70美元,反映促銷折扣、非全療程病例較高的成長,並包含25美元的不利匯率影響,部分被價格上調所抵銷。
Total Q4 Invisalign shipments of 333,800 cases were up 4.5% sequentially and up 30.9% year-over-year.
第四季Invisalign總出貨量為333,800例,較前一季成長4.5%,較去年同期成長30.9%。
For Americas orthodontists, Q4 Invisalign case volume was slightly lower than our Q4 outlook, primarily due to longer cycle times in Latin America, and was down 2.9% sequentially and up 24.7% year-over-year. For Americas GP dentists, Invisalign case volume was up 3.2% sequentially and up 17.3% year-over-year. For international doctors, Invisalign case volume was up 12.2% sequentially and up 45.3% year-over-year.
就美洲地區矯正科醫師而言,第四季Invisalign病例量略低於我們對第四季的展望,主要因拉丁美洲的週期時間較長;病例量較前一季下降2.9%,較去年同期成長24.7%。就美洲地區一般牙醫(GP)而言,Invisalign病例量較前一季成長3.2%,較去年同期成長17.3%。就國際市場醫師而言,Invisalign病例量較前一季成長12.2%,較去年同期成長45.3%。
Our scanner and services revenue for the fourth quarter was $88.4 million, up 13% sequentially due to volume increases in Americas and EMEA. Year-over-year revenue was up 54.8%, primarily due to higher scanner units across regions.
第四季掃描儀與服務營收為8,840萬美元,因美洲與EMEA出貨量增加,較前一季成長13%。年對年營收成長54.8%,主要由各地區掃描儀出貨台數增加所帶動。
Moving on to gross margin. Fourth quarter overall gross margin was 71.7%, down 1.9 points sequentially and down 3.8 points year-over-year. Clear aligner gross margin for the fourth quarter was 74.1%, down 1.2 points sequentially, primarily due to higher number of aligners per case, higher freight cost, reflecting faster international growth, higher training cost due to more doctors trained in the quarter and manufacturing spend driven by operational expansion in China, which was partially offset by slightly higher Invisalign ASPs. Clear aligner gross margin was down 3.5 points year-over-year, primarily due to higher number of cases per -- aligners per case, lower ASPs, higher training costs and freight charges and regional expansion of our manufacturing-related activities in China and EMEA.
接著談毛利率。第四季整體毛利率為71.7%,較前一季下降1.9個百分點,較去年同期下降3.8個百分點。第四季隱形矯正器毛利率為74.1%,較前一季下降1.2個百分點,主要原因為每案矯正器數量增加、運費成本上升(反映國際業務成長加速)、本季受訓醫師人數增加導致訓練成本提高,以及因中國營運擴張帶動的製造支出增加;上述影響部分被Invisalign平均銷售單價(ASP)略為提高所抵銷。隱形矯正器毛利率較去年同期下降3.5個百分點,主要原因為每案矯正器數量增加、ASP下降、訓練成本與運費上升,以及我們在中國與EMEA地區擴大與製造相關活動的區域布局。
Scanner gross margin for the fourth quarter was 59.9%, down 4 points sequentially and down 2.1 points year-over-year, primarily due to manufacturing and freight costs and lower ASP.
第四季掃描器毛利率為59.9%,較前一季下降4個百分點,較去年同期下降2.1個百分點,主要原因為製造與運輸成本以及ASP下降。
Q4 operating expenses were $262.6 million, up sequentially 6.5% and up 26.1% year-over-year. The sequential increase in operating expenses primarily reflects our continued investment in sales and R&D activities along with higher legal, consulting expenses, partially offset by seasonality lower advertising spending. Year-over-year, the increase in operating expenses reflects higher spending commensurate with growth.
第四季營業費用為2.626億美元,較前一季增加6.5%,較去年同期增加26.1%。營業費用的季增主要反映我們持續投資於銷售與研發活動,以及法律與顧問費用增加,部分被季節性因素導致的廣告支出下降所抵銷。年增方面,營業費用增加反映與成長相匹配的較高支出。
Our fourth quarter operating income was $120.5 million, down 3.8% sequentially and up 9.9% year-over-year. The sequential decrease in operating income is primarily attributed to lower gross margin and higher operating expenses as mentioned earlier. On a year-over-year basis, the increase in operating income primarily reflects higher revenue offset by higher sales and marketing, R&D, legal/consulting spending and unfavorable foreign exchange.
第四季營業利益為1.205億美元,較前一季下降3.8%,較去年同期增加9.9%。營業利益的季減主要歸因於前述毛利率下降以及營業費用上升。年增方面,營業利益增加主要反映營收提高,但被較高的銷售與行銷、研發、法律/顧問支出以及不利的外匯影響所抵銷。
Our fourth quarter operating margin was 22.6%, down 2.2 points sequentially and down 3.4 points year-over-year. The sequential decrease in operating margin is primarily due to lower gross margin, as mentioned earlier. On a year-over-year basis, the decrease in operating margin is primarily due to lower gross margin as described earlier and about 0.5 points impact from unfavorable foreign exchange.
第四季營業利益率為22.6%,較前一季下降2.2個百分點,較去年同期下降3.4個百分點。營業利益率的季減主要由前述毛利率下降所致。年減方面,主要原因為前述毛利率下降,以及約0.5個百分點來自不利的外匯影響。
With regards to fourth quarter tax provision, our tax rate was 8.5% (sic) [18.5%], which includes approximately $1.9 million in excess tax benefits related to stock-based compensation.
關於第四季所得稅費用,我們的稅率為8.5%(原文如此)[18.5%],其中包含約190萬美元與股票基礎薪酬相關的超額稅務利益。
Fourth quarter diluted earnings per share was $1.20, down $0.04 sequentially and up $1.07 compared to the prior year.
第四季稀釋後每股盈餘為1.20美元,較前一季下降0.04美元,較去年同期增加1.07美元。
Moving on to the balance sheet. As of the fourth quarter, cash, cash equivalents and marketable securities, including both short and long-term investments, were $744.5 million, an increase of approximately $131.3 million from the prior quarter, which is primarily due to higher cash flow from operations. Of our $744.5 million of cash, cash equivalents and marketable securities, $432.5 million was held in the U.S. and $312 million was held by our international entities.
接著談資產負債表。截至第四季,現金、約當現金與有價證券(包含短期與長期投資)為7.445億美元,較前一季增加約1.313億美元,主要由營運現金流增加所致。在7.445億美元的現金、約當現金與有價證券中,4.325億美元存放於美國,3.12億美元由我們的海外實體持有。
Q4 accounts receivable balance was $439 million, up approximately 4.5% sequentially. Our overall day sales outstanding was 74 days, down 1 day sequentially and up 5 days as of Q4 last year.
第四季應收帳款餘額為4.39億美元,較前一季增加約4.5%。整體應收帳款週轉天數(DSO)為74天,較前一季減少1天,較去年第四季增加5天。
Cash flow from operations for the fourth quarter was $241.3 million, up $79 million compared to the prior year. Free cash flow for the quarter, defined as cash flow from operations less capital expenditures, amounted to $187 million.
第四季營運活動現金流為2.413億美元,較去年同期增加7,900萬美元。本季自由現金流(定義為營運活動現金流減資本支出)為1.87億美元。
Capital expenditures for the fourth quarter were $54.3 million, primarily related to our continued investment in increasing aligner capacity and facilities.
第四季資本支出為5,430萬美元,主要與我們持續投資以提升矯正器產能與設施相關。
During Q4, we repurchased $50 million of stock against our stock buyback authorizations and have $500 million still available for repurchase under the May 2018 repurchase program.
第四季期間,我們依據股票回購授權回購了5,000萬美元的股票;在2018年5月的回購計畫下,仍有5億美元可供回購。
Before we move to the Q1 outlook, I would like to make a few comments on our full year 2018 results. In 2018, we shipped a record 1.2 million Invisalign cases, up 31.9%. This reflects 45% volume growth for our international doctors and 24.2% volume growth from our Americas doctors. Shipments of our iTero scanner were up 77.2% versus 2017.
在進入第一季展望之前,我想先就2018年全年業績做幾點說明。2018年我們出貨創紀錄的120萬件Invisalign病例(cases),成長31.9%。這反映我們國際醫師出貨量成長45%,以及美洲地區醫師出貨量成長24.2%。我們iTero掃描器出貨量較2017年成長77.2%。
Total revenue was a record $2 billion, up 33.5% year-over-year with Invisalign revenues of $1.7 billion.
總營收創紀錄達20億美元,較去年同期成長33.5%,其中Invisalign營收為17億美元。
Full year operating income of $466.7 million, up 31.9% versus 2017 and operating margin at 23.7%.
全年營業利益為4.667億美元,較2017年成長31.9%,營業利益率為23.7%。
Free cash flow was $331.4 million.
自由現金流為3.314億美元。
For the year, we repurchased 1.1 million shares of Align stock for $300 million. 2018 diluted earnings per share was $4.92.
全年我們以3億美元回購了110萬股Align股票。2018年稀釋後每股盈餘為4.92美元。
With that, let's turn to our Q1 outlook and the factors that inform our view, starting with the demand outlook. For international, we expect Q1 to be up sequentially as the EMEA market maintains momentum from Q4 and APAC is seasonally flat sequentially as some markets observe the Lunar New Year holiday. For Americas, we expect Q1 to also increase sequentially with strong growth from North America orthos and a slight increase in North America GPs. We expect Latin America to be down sequentially given this is their summer holiday season.
接下來我們談第一季展望,以及支撐我們觀點的因素,先從需求展望開始。就國際市場而言,我們預期第一季將較前一季成長,因EMEA市場延續第四季動能,而APAC因部分市場適逢農曆新年假期,季節性因素使其與前一季大致持平。就美洲市場而言,我們預期第一季也將較前一季增加,北美矯正專科(orthos)維持強勁成長,北美全科牙醫(GPs)則小幅增加。我們預期拉丁美洲將較前一季下滑,因為當地正值暑假假期季。
We expect our iTero business to be down slightly from a record Q4, consistent with seasonal trends and capital equipment market. And we continue to expect minimal volume from SmileDirectClub.
我們預期iTero業務將較創紀錄的第四季小幅下滑,符合季節性趨勢與資本設備市場狀況。我們仍預期來自SmileDirectClub的出貨量極少。
With this as a backdrop, we expect the first quarter to shape up as follows. Invisalign's case volume is expected to be in a range of 340,000 to 345,000 cases, up approximately 25% to 27% year-over-year.
在此背景下,我們預期第一季表現如下。Invisalign病例量預期介於34萬至34.5萬件,較去年同期約成長25%至27%。
We expect Q1 revenues to be in the range of $525 million to $535 million, reflecting increased volume and flat ASPs versus Q4 2018. We expect Q1 gross margin to be in the range of 70.3% to 71%, reflecting our higher start-up costs in China and increased doctor training expenses. We expect Q1 operating expenses to be in a range of $290 million to $294 million, which reflects our sales force expansion and increased legal expenses. Q1 operating margin should be in a range of 15.1% to 16.1%.
我們預期第一季營收介於5.25億至5.35億美元,反映出貨量增加,且ASP相較2018年第四季持平。我們預期第一季毛利率介於70.3%至71%,反映中國較高的啟動成本以及醫師訓練費用增加。我們預期第一季營業費用介於2.90億至2.94億美元,反映銷售團隊擴編以及法律費用增加。第一季營業利益率應介於15.1%至16.1%。
Our effective tax rate should be approximately 16%, which is higher than 2018 due to nondeductible officer stock compensation based on recent IRS guidance and a lower stock price. We expect approximately $3 million to $4 million equity loss related to our share of SmileDirectClub's net losses. And diluted shares outstanding should be approximately $80.9 million, exclusive of any share repurchases. Taken together, we expect our Q1 diluted earnings per share to be in a range of $0.78 to $0.84. In addition, as we continue our operational expansion efforts, we expect CapEx for Q1 to be approximately $60 million to $65 million. And we expect depreciation and amortization to be $19 million to $20 million.
我們的有效稅率應約為16%,高於2018年,原因是依據近期IRS指引,主管股票薪酬屬不可扣抵項目,且股價較低。我們預期與我們分攤SmileDirectClub淨損失相關的權益法損失約300萬至400萬美元。稀釋後流通在外股數應約為8,090萬股,不包含任何股票回購。綜合以上,我們預期第一季稀釋後每股盈餘介於0.78至0.84美元。此外,隨著我們持續推動營運擴張,我們預期第一季資本支出約為6,000萬至6,500萬美元。我們預期折舊與攤銷為1,900萬至2,000萬美元。
Now let me turn to our view for the full year 2019, notwithstanding the impact of foreign exchange rates. We expect total revenue growth for the company, Invisalign and iTero, to be in the middle range of our long-term operating model of 20% to 30%. We anticipate Invisalign ASPs to be flat from Q4 2018, reflecting continued growth from international regions, increased share of the teen segment and uptake of noncomprehensive products. We anticipate Invisalign volume to be in the middle of the range of our long-term model target of 20% to 30%.
現在讓我在不考慮外匯匯率影響的情況下,談談我們對2019年全年的看法。我們預期公司整體(Invisalign 與 iTero)的總營收成長,將落在我們長期營運模型20%至30%的中段區間。我們預期 Invisalign 的平均銷售價格(ASP)將較2018年第四季持平,反映國際地區持續成長、青少年(teen)客群占比提升,以及非全套(noncomprehensive)產品採用率提高。我們預期 Invisalign 出貨量將落在我們長期模型目標20%至30%區間的中段。
We anticipate gross margin and operating margin to improve over the course of the year. We anticipate gross margin to approach our long-term model target of 73% to 78% by Q4.
我們預期毛利率與營業利益率將在全年逐步改善。我們預期毛利率到第四季將接近我們長期模型目標的73%至78%。
We will continue to fuel growth globally and expect to invest in international and operational expansion as well as sales and marketing initiatives, including nearly 100 new sales reps in Americas hired at the end of Q4 and an additional GP sales reps in EMEA beginning in Q1. These investments also include continued litigation expenses to protect our intellectual property and extend our competitive advantage.
我們將持續在全球推動成長,並預期投資於國際與營運擴張,以及銷售與行銷計畫,包括在第四季末於美洲地區新聘近100名業務代表,並自第一季起在EMEA增聘額外的GP業務代表。這些投資也包括持續的訴訟費用,以保護我們的智慧財產並延伸我們的競爭優勢。
Given our continued growth and expansion internationally, during the year, we intend to reorganize our corporate structure and intercompany relationships to more closely align with the international nature of our business activities. The proposed corporate structure may also allow us to obtain financial and operational efficiencies after they are implemented. As a result, we will incur expenses in the near term and expect to realize the related benefits in subsequent years. We expect our operating margin for the second half to be in the long-term model of 25% to 30%.
鑑於我們持續成長並在國際市場擴張,我們計畫在今年內重整公司架構與關係企業(intercompany)之間的關係,使其更貼近我們業務活動的國際化特性。擬議的公司架構在落實後,也可能使我們取得財務與營運效率。因此,我們短期內將產生費用,並預期在後續年度實現相關效益。我們預期下半年營業利益率將落在長期模型的25%至30%。
For the full year, we anticipate operating margin to be below our long-term target as it includes approximately 1.5 to 2 points impact from increased legal fees and the planned corporate structure reorganization. We expect the equity loss for our investment in SmileDirectClub to be $3 million to $4 million per quarter. We expect our tax rate for 2019 to be approximately 24%, which includes about $8 million of excess tax benefits. 2019 tax rate is higher than 2018 primarily due to a release of unrecognized tax benefits that will not repeat.
就全年而言,我們預期營業利益率將低於長期目標,因其中包含因法律費用增加及規劃中的公司架構重整所帶來約1.5至2個百分點的影響。我們預期對 SmileDirectClub 投資的權益法損失每季為300萬至400萬美元。我們預期2019年的稅率約為24%,其中包含約800萬美元的超額稅務利益(excess tax benefits)。2019年稅率高於2018年,主要是因2018年有釋放未認列稅務利益(unrecognized tax benefits),該項目不會重複發生。
We expect our earnings power in the second half of the year to be stronger than the first half with second half operating results to account for somewhere in the range of 50% to 55% of our full year results. We expect capital expenditures for 2019 to be in the range of $250 million to $260 million.
我們預期今年下半年的獲利能力將強於上半年,下半年營運結果將約占全年結果的50%至55%。我們預期2019年的資本支出將介於2.5億至2.6億美元。
With that, I'll turn it back over to Joe for final comments. Joe?
接下來,我把時間交回給Joe做最後的結語。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, John, and thanks to those who joined our call today. Overall, 2018 was a great year for Align, and I'm very pleased with the strong performance for Invisalign and iTero across all key regions, customers, channels and products. This year, not only do we celebrate our 21st year in business, we also achieved several major milestones, including our 6 millionth Invisalign patient and $2 billion in revenue for the first time. It took nearly 20 years to reach our first $1 billion in sales and only 2 years to reach our second billion dollars.
謝謝你,John,也謝謝今天加入我們電話會議的各位。整體而言,2018年對Align來說是非常出色的一年,我對Invisalign與iTero在所有主要地區、客戶、通路與產品上的強勁表現感到非常滿意。今年,我們不僅慶祝公司成立第21年,也達成數個重要里程碑,包括第600萬位Invisalign患者,以及營收首次突破20億美元。我們花了將近20年才達到第一個10億美元的銷售額,而只花了2年就達到第二個10億美元。
We also delivered on our strategic growth drivers with new product and technology innovation, expansion of our manufacturing and treatment planning operations, and raising awareness of Invisalign treatment with consumers and engaging with them in more innovative ways than ever before.
我們也透過新產品與技術創新、擴大製造與治療規劃(treatment planning)營運,以及提升消費者對Invisalign療程的認知並以比以往更創新的方式與其互動,落實了我們的策略性成長動能。
As I step back and look ahead to 2019 and beyond, I want to reinforce the importance of the investments we're making to drive growth globally. The underlying opportunity for doctors and their patients is expanding based on digital technology that Align has spent over 21 years developing. And while we have a huge amount of accumulated expertise and knowledge in digital technology and orthodontics, we have to ensure that we have the capabilities to further expand and regionalize our operations, extend our competitive lead and protect our business from companies willing to take shortcuts with respect to intellectual property. It is incumbent upon us to drive the transition to a fully digital workflow and continue to deliver new products and services that not only benefit Invisalign doctors but their patients and consumers alike.
當我退一步展望2019年及更長遠的未來時,我想再次強調我們為推動全球成長所進行投資的重要性。醫師及其患者的根本機會正在擴大,這是建立在Align投入超過21年所發展的數位技術之上。雖然我們在數位技術與齒顎矯正領域累積了大量專業與知識,但我們必須確保具備進一步擴大並區域化營運的能力、延伸我們的競爭領先地位,並保護我們的業務免受那些願意在智慧財產方面走捷徑的公司影響。我們有責任推動全面數位化工作流程的轉型,並持續提供新產品與服務,不僅讓Invisalign醫師受益,也讓其患者與消費者同樣受益。
Following our Ortho Summit in November, I met with hundreds of Invisalign doctors and their staff, I had the opportunity to travel to our regional kickoff meetings and connect with Align team members at every level of our organization to hear their detailed plans of the upcoming year. While I spent more of my time at the Americas kickoff because of my interim role as Americas leader, I can say unequivocally that across the company, the excitement and level of engagement surrounding our business and market opportunity was palpable.
在11月的Ortho Summit之後,我與數百位Invisalign醫師及其團隊會面,也有機會前往各區域的年度啟動會議,並與組織各層級的Align團隊成員交流,聆聽他們對來年詳細的規劃。雖然因我暫代美洲區領導職務而在美洲區啟動會議投入較多時間,但我可以明確地說,在全公司範圍內,圍繞我們業務與市場機會的興奮感與投入程度是顯而易見的。
Overall, the demand profile globally is solid and nothing we see in the environment suggest otherwise. We're running the plays we know and are confident we can bring greater efficiencies, economies of scale and know that adding sales training to get closer to customers in local markets creates sustainable competitive advantage.
整體而言,全球需求態勢穩健,我們在外部環境中所看到的情況也沒有任何相反的跡象。我們正執行我們熟悉且有效的策略,並有信心能帶來更高效率與規模經濟;同時也深知,透過增加銷售訓練以更貼近在地市場的客戶,能創造可持續的競爭優勢。
Finally, as most of you know, one of the key orthodontic journals in North America is the Journal of Clinical Orthodontics, and I often flip through it and ask why there aren't more clear aligners profiled. This week, I was caught off guard when I opened the December issue and found it dedicated entirely to clear aligner therapy. Bob Keim is the editor of the JCO and has been to many of our Invisalign Summits. In meetings with him and reading his editorials, I knew he supported Invisalign treatment and clear aligners in general, but it was never clear to me to the extent he believed in clear aligner technology as we've seen in the most recent issue of the JCO, especially the editor's column, "The End of Braces?" If you haven't had a chance to read the JCO, you should. Bob could not take a stronger position for clear aligners. He acknowledges that he may take some flak for being so bold, but I believe his strong endorsement is a major breakthrough for Align and digital orthodontics.
最後,如各位多數人所知,北美其中一本重要的齒顎矯正期刊是《Journal of Clinical Orthodontics》,我常常翻閱並納悶為什麼被介紹的透明矯正器(clear aligners)案例不更多。本週我打開12月號時有些意外,因為整期內容完全 посвящ於透明矯正器治療。Bob Keim是JCO的編輯,也參加過我們多次Invisalign Summit。在與他會面以及閱讀他的社論時,我知道他支持Invisalign療程與透明矯正器整體發展,但我從未清楚他對透明矯正器技術的信念程度,直到我們在最新一期JCO中看到,尤其是編者專欄〈牙套的終結?〉("The End of Braces?")。如果你還沒有機會閱讀JCO,你應該去讀一讀。Bob對透明矯正器的立場不可能更強烈。他也承認自己可能會因如此大膽而受到一些批評,但我相信他強而有力的背書,對Align與數位齒顎矯正而言是一項重大突破。
With that, I want to thank you, again for joining our call. I look forward to updating you on our progress as the year unfolds. We'll see many of you at the Chicago Midwinter Meeting next month as well as industry and financial conferences throughout the year. Now I'll turn the call over to the operator for questions. Operator?
說到這裡,我想再次感謝各位參與我們的電話會議。我期待在今年進展的過程中,向各位更新我們的成果。下個月我們也會在芝加哥Midwinter Meeting見到許多各位,並在全年各項產業與金融研討會上與各位交流。現在我把電話交給接線員進行提問。接線員?
Operator
Operator
(Operator Instructions) Our first question comes from the line of Robert Jones with Goldman Sachs.
(接線員指示) 我們的第一個問題來自高盛(Goldman Sachs)的Robert Jones。
Robert Patrick Jones - VP
Robert Patrick Jones - VP
I guess, just to start on ASPs. Joe, could you maybe talk through the progression of ASPs that you saw over the quarter? On a worldwide basis, certainly seems like you guys were able to stabilize ASPs in 4Q relative to 3Q and looking at the implied guidance from 1Q, seems like that's expected to continue, and in the full year, you're calling for that to be at the kind of level we should look for. So I guess, just how did they progress throughout 4Q? And then just related to that, what are the major pushes and pulls as you think about ASPs over the course of '19?
我想先從ASP談起。Joe,你能否說明一下你們在本季看到的ASP變化走勢?以全球來看,你們似乎在第四季相較第三季成功穩定了ASP;而從第一季的隱含指引來看,似乎也預期這種情況會延續,並且在全年你們也表示應以這樣的水準作為觀察基準。所以我想問,第四季期間ASP是如何演變的?另外,延伸這個問題,當你們看2019年全年ASP走勢時,主要的推力與拉力因素是什麼?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Bob, that's a big question, but I'll make it simple, okay? We had an issue in the third quarter in the Americas with our Advantage Program that I think kicked off this ASP concern. As we said we would do, we retracted that $300 that we offered on teens and also adults at that point in time. After that, basically, out ASPs are what they normally are, in the sense of mixes and matches across the spectrum of EMEA in different places. So I mean, that's the total -- you want to talk about we had an exchange hit this quarter also but again, I think we prepared you for that in the last quarter. So overall, the only change is we didn't have an advantage issue in the third quarter as in the fourth quarter.
Bob,這是個大問題,但我會把它講簡單,好嗎?我們在美洲地區第三季的 Advantage Program 出了點狀況,我認為這引發了大家對 ASP 的疑慮。如同我們說過會做的,我們把當時針對青少年以及成人所提供的 300 美元優惠收回。之後,基本上,我們的 ASP 就回到正常水準,也就是在 EMEA 各地依不同市場出現的產品組合與搭配所形成的正常結構。所以我的意思是,這就是全部——如果你想談的話,我們這一季也受到匯率影響,但我想我們在上一季已經讓大家有心理準備了。所以整體而言,唯一的變化是:第四季不像第三季那樣有 Advantage 的問題。
Robert Patrick Jones - VP
Robert Patrick Jones - VP
Yes. I guess just to follow on, on that, Joe. I mean, I think the question really is as you think about '19, obviously, those programs go away. I guess, the expectation looks like here in the slides that you're still thinking that it's going to be flat to the 4Q level. So just trying to understand a little bit better what could move the ASPs up over the course of the year as we think about some of the things that hopefully, would not reoccur in '19 as happened in '18.
是。我想就此再追問一下,Joe。我的意思是,我認為問題的核心是:當你們看 2019 年時,顯然那些方案會取消。我想,從投影片上看起來,你們仍然認為 ASP 會與第四季水準持平。所以我只是想更清楚了解:在一年當中,有哪些因素可能推動 ASP 上升——尤其是我們希望 2019 年不會再發生 2018 年那些狀況。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes, John will jump in on this.
是,John 會補充說明。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Bob, this is John. So the couple of positive mix that we talk a lot about, the international growth, we continue to see strong growth internationally. Mandibular advancement in the U.S. contributes overall to our teen growth, which are comprehensive cases and does help. And we are also seeing growth on the noncomprehensive side. So we think those 3, we've seen some balance and that's what we would expect for 2019.
Bob,我是 John。我們常談到的幾個正向組合因素之一是國際成長,我們持續看到海外市場強勁成長。在美國,下顎前移(mandibular advancement)整體上帶動我們的青少年成長,這些屬於全療程(comprehensive)病例,確實有幫助。而且我們也看到非全療程(noncomprehensive)方面的成長。所以我們認為這三項因素之間已出現一些平衡,而這也是我們對 2019 年的預期。
Robert Patrick Jones - VP
Robert Patrick Jones - VP
Great. And then I guess just a follow-up from me, John, while I have you. If you think about the margin outlook for the year, it looks like you guys are calling for the growth in operating margins to get into the long-term ranges in the back half. Just at a high level, I guess, how much visibility and control do you guys have over that trajectory into the back half of '19 around the margins?
很好。那我再追問一下,John,趁我還在線上。如果你看今年的毛利率/利潤率展望,你們似乎預期營業利益率的成長會在下半年進入長期區間。就高層次來說,我想問的是:對於 2019 年下半年利潤率走勢,你們對這條軌跡有多少能見度與掌控度?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, Bob. It really starts with some of the manufacturing efficiencies that we expect to get as we start to ramp up in China and continue to ramp up with our treatment planning. We'll see that continue to ramp as we move through the year. We have other products and programs that will also help us from a mix standpoint as well. So we feel really good about how we're -- how we view the year and the expectation of margin improvement throughout the year.
是的,Bob。這主要從我們預期能取得的一些製造效率開始,因為我們開始在中國擴產爬坡,並且持續在治療計畫(treatment planning)方面擴量。隨著一年推進,我們會看到這些持續爬坡。我們也有其他產品與方案,從產品組合角度也會對我們有幫助。所以我們對我們如何看待今年、以及全年利潤率逐步改善的預期,都感到非常有信心。
Operator
Operator
Our next question comes from the line of Elizabeth Anderson with Evercore ISI.
下一個問題來自 Evercore ISI 的 Elizabeth Anderson。
Elizabeth Hammell Anderson - Associate
Elizabeth Hammell Anderson - Associate
I was wondering if you could talk to us a little bit more about the reorganization expenses. Are you sort of thinking of those on an ongoing basis or more onetime? I guess, my question stems in part because I was wondering if you were thinking about perhaps potentially backing those out of your 2019 results?
我想請問你們能否再多談一些重組費用(reorganization expenses)。你們是把它視為持續性支出,還是比較偏一次性?我這樣問的部分原因是:我在想你們是否考慮在 2019 年的結果中把這些費用剔除(backing those out)?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Elizabeth, this is John. This is a onetime. I mean, it's -- as the company expands and grows internationally, it's looking at some of the efficiencies that we can gain through that change. And we report numbers on a GAAP basis. We'll continue to do so, but we'll give you highlights as the year goes on as update.
Elizabeth,我是 John。這是一次性的。我的意思是——隨著公司擴張並在國際上成長,我們會檢視透過這項變革可以取得哪些效率。而我們是以 GAAP 基礎來報告數字。我們會持續如此,但也會在年度進行中提供重點說明作為更新。
Elizabeth Hammell Anderson - Associate
Elizabeth Hammell Anderson - Associate
Okay. That's helpful. And I guess, also can you just talk a little bit more about the sales investments that you guys are making into the Americas in terms of any particular details you could provide on that? That would be helpful.
好的。這很有幫助。另外,你們能否再多談一些你們在美洲地區所做的銷售投資?如果能提供任何更具體的細節,會很有幫助。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes, Elizabeth. It's Joe. Look, in Americas, we're still really underpenetrated in the marketplace, particularly on the GP segment, and so we decided we'd add 100 salespeople. We feel really good about that investment giving us good short-term returns. We've done this before almost in every cycle since I've been here. It's a play we know how to run, and we know the importance of it overall. So don't look at it as an anomaly. It's just a continuation of building out our sales force and taking advantages of some of the man out there. Elizabeth, I'll also tell you. It's a high touch thing. You have to touch doctors in this business to drive sales. It's really -- and it -- this doesn't happen on itself. It's -- there's a constant touch to it. So we're really aware of that. Often, our treatment is much different than what these doctors have done before. Our salespeople, we train them well clinically but also from a business standpoint so that they can talk about clinically how to use a product line but also from a business standpoint how you integrate it into the practice. So adding salespeople is really important.
好的,Elizabeth。我是 Joe。你看,在美洲地區,我們在市場上的滲透率仍然偏低,尤其是在 GP(一般牙醫)這個區隔,因此我們決定新增 100 位業務人員。我們對這項投資能帶來良好的短期回報很有信心。自從我在這裡以來,幾乎每個週期我們都做過類似的事。這是一套我們知道怎麼執行的打法,我們也知道它整體的重要性。所以不要把它看成異常。這只是持續擴建我們的銷售團隊,並把握外部的一些人力資源優勢。Elizabeth,我也想補充。這是一個高接觸(high touch)的事情。在這個產業,你必須與醫師保持接觸才能推動銷售。這真的——而且——不會自動發生。這需要持續不斷的接觸。所以我們非常清楚這點。很多時候,我們的治療方式與這些醫師過去做的很不一樣。我們會把業務人員在臨床面訓練得很好,也會在商業面訓練,讓他們能從臨床角度說明如何使用產品線,也能從經營角度說明如何把它整合進診所。所以增加業務人員非常重要。
Operator
Operator
Our next question comes from the line of Jonathan Block with Stifel.
下一個問題來自 Stifel 的 Jonathan Block。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
I think the paranoia is going to sort of move from ASPs to volumes and margins tomorrow. So maybe on the margin side, John, for '19, you mentioned expectations to be below your long-term op margin goal of 25% to 30%. Specifically, you called out 150 to 200 bps from increased legal fees in the reorg. So a couple of questions there. Is that reorg all specific to '19? And then if we were to normalize for the 150 to 200 bps, would your '19 op margin approach the lower band of your long-term 25% to 30% goal? And then I got a quicker follow-up.
我想大家的焦慮明天可能會從 ASP 轉到量與利潤率。所以也許先談利潤率這邊,John,對於 2019 年,你提到預期會低於你們長期 25% 到 30% 的營業利益率目標。你特別指出重組帶來的法律費用增加,會影響 150 到 200 個基點。所以這裡有幾個問題。這個重組是否全部都只發生在 2019 年?另外,如果我們把這 150 到 200 個基點正常化(normalize)排除,你們 2019 年的營業利益率是否會接近你們長期 25% 到 30% 目標區間的下緣?然後我還有一個更快的追問。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, that's the right way to look at it, Jon. So this is 2019 expenses. And these expenses, we think we would have been in the long-term range that we have of 25% to 30% if we didn't have these expenses.
是的,Jon,這樣看是對的。所以這些是 2019 年的費用。而我們認為,如果沒有這些費用,我們本來會落在我們所說的 25% 到 30% 的長期區間內。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Okay. Long question, short answer. I'll take it. And then maybe, Joe, for you, on the vols. Just any more color. I mean, any thoughts on the North American ortho weakness? I do have a hard time believing that all the weakness was Latin America just looking at the size of that business. But anything more North American ortho weakness? Is this a pause before mandibular and Invisalign First take greater hold in 2019? And maybe, if you don't mind, any thoughts on what MAF and First could contribute to North America this year?
好的。長問題、短答案。我接受。那接著可能問你,Joe,關於量(vols)。能否再多給一些說明?我的意思是,對北美矯正(ortho)疲弱有什麼看法?光看拉丁美洲業務的規模,我很難相信疲弱全部都來自拉丁美洲。但對北美矯正的疲弱還有什麼補充嗎?這是否是在 2019 年 mandibular 和 Invisalign First 更加普及之前的一段暫停?另外,如果你不介意,對於 MAF 和 First 今年可能對北美帶來多少貢獻,有什麼想法?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Jon, look, I -- the America's growth this year, I know we had the blip in the third quarter overall, but 2018 is a good year for us. If you look at the last 6 years, this is actually the second highest growth profile we've had. America's grows about 17% on an average over those 6 years. The orthos grew -- this is the only -- this is the second -- from a percentage standpoint, best year we've had from an ortho standpoint. What happened between the third and fourth quarter, again, we think it was a -- that I mentioned on my opening, was the uptake that we have with that Advantage Program in the third quarter. And that was repeated in the fourth quarter, and we think we have this quarter-over-quarter kind of discrepancy. GP is at an all-time high from a growth standpoint overall. And then obviously, from a Brazil standpoint, too, it's starting to become material in the sense of the size of that business, and we're looking for good contributions this year. So Jon, I don't know if I've answered your question. But I'd say then if you look at the volume overall, you see how strong EMEA has been. The expansion of EMEA, into areas like Turkey and Russia and the Middle East, has been important to us. But also France is growing well. Spain has been strong. Italy came back. We saw it. We've had great success with Go in -- with the GPs out of the U.K. but also in Germany, too. So we really feel great about that region. And then APAC, again, we see strength. We've seen strength in China. We see strength in APAC overall. Japan's growth has been phenomenal. And then bleed that in with our iTero growth, too, that you've seen across the spectrum. Overall, we feel good about volume.
Jon,你看,我——美國今年的成長,我知道我們在第三季整體上有個小波動,但2018年對我們來說是個好年。如果你看過去6年,這其實是我們第二高的成長曲線。美國在這6年期間平均成長約17%。矯正(ortho)成長——這是唯一——這是第二——就百分比而言,這是我們在矯正業務方面表現最好的第二年。第三季到第四季之間發生了什麼,再次,我們認為那是——我在開場時提到的——第三季我們的 Advantage Program 帶來的採用率提升。而第四季也重複出現,我們認為因此出現了這種季對季的差異。從整體成長角度來看,GP 達到歷史新高。然後很明顯地,從巴西的角度來看,隨著該業務規模擴大,也開始變得具有實質性,我們期待今年會有良好貢獻。所以 Jon,我不確定我是否回答了你的問題。但我會說,如果你看整體的量,你會看到 EMEA 有多強勁。EMEA 擴展到土耳其、俄羅斯和中東等地區,對我們很重要。但法國也成長得很好。西班牙一直很強。義大利回來了。我們看到了。我們在英國的 GP(一般牙醫)端推動 Go 方面取得了很大成功,但在德國也是如此。所以我們對那個區域真的感覺很好。然後 APAC,同樣地,我們看到強勁。我們在中國看到強勁。我們看到 APAC 整體都很強。日本的成長非常驚人。再把你在各個面向都看到的 iTero 成長也一起納入。整體而言,我們對出貨量感到樂觀。
Operator
Operator
Our next question comes from the line of Brandon Couillard with Jefferies.
我們下一個問題來自 Jefferies 的 Brandon Couillard。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
Just a couple of housekeeping items, John, in terms of the fourth quarter. Could you quantify the impact in Latin America from the longer cycle times? And you expect that to normalize in the first quarter? And then in terms of the fourth quarter OpEx, it looks like it was about $12 million above your guidance, which is very atypical and unusual. Can you point us to the areas of spend that -- were perhaps accelerated or brought you in above your plan?
John,我有幾個例行性的問題,關於第四季。你能量化一下拉丁美洲因為週期時間拉長所造成的影響嗎?你預期第一季會恢復正常嗎?另外,第四季的營業費用(OpEx)看起來比你們的指引高出約1,200萬美元,這非常不典型也很罕見。你能指出哪些支出項目——可能是提前發生或使你們高於原先計畫——嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. So for the fourth quarter in Latin America, I mean, it's a growing business, as Joe said, and it's a couple of thousand cases that were kind of in transition on a -- from -- right at the end of the fourth quarter. And then as far as spend, were you specifically talking about spend in fourth quarter or compared to the guide in the first quarter?
是。所以就拉丁美洲第四季而言,我的意思是,正如 Joe 所說,這是一個成長中的業務,有幾千個案例在第四季末的那個時間點,處於某種——從——轉換中的狀態。至於支出方面,你是特別指第四季的支出,還是相對於第一季指引的比較?
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
Yes, the fourth quarter OpEx relative to your guidance.
是的,第四季的營業費用(OpEx)相對於你們的指引。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. We saw added litigation expenses as we've been going -- as a part of our process that we have on the legal side. There's some added costs that we're showing there. And as Joe said, we added some salespeople, and some of that, those hires and those expenses came into fourth quarter. But we wanted people on the ground and ready to be able to sell and give us volume as soon as possible into 2019. So some of those costs hit there as well.
是。我們看到訴訟費用增加,因為我們在法律端——作為我們流程的一部分——持續推進。那裡顯示出一些額外成本。另外如 Joe 所說,我們增聘了一些業務人員,其中部分招募與相關費用落在第四季。但我們希望人員能在第一線就位並準備好銷售,讓我們在2019年能盡快帶來出貨量。所以其中一些成本也反映在那裡。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
And coming back to ASPs for 2019. It would seem to imply that worldwide ASPs for the year would be down about 3% year-over-year. I understand currency is probably half of that. Mix is another dynamic. But would it be your expectation that promotional activity would be sort of consistent year-over-year? Or is there some cushion built in perhaps for more, I guess, promo activity in '19 relative to last year?
再回到2019年的 ASP(平均銷售價格)。看起來意味著全年全球 ASP 會年減約3%。我理解匯率可能占其中一半。產品組合(mix)是另一個因素。但你是否預期促銷活動會大致與去年一致?或者你們是否在指引中預留了一些緩衝,假設2019年的促銷活動會比去年更多?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
I would say there's nothing that specifically that we're looking at additional promotions or others. We look at the business as we have various products and new products that come out, changes that we make. We look at promotions to be able to drive volume and drive uptake across the regions. So they vary by region, but nothing out of the ordinary. And we were pleased to see where ASPs finished and have a good expectation of -- given the positive growth internationally, the positive growth that we see on teens, and we're seeing strong noncomprehensive growth. All that taking into account keeps us flat for ASPs.
我會說,我們沒有特別在看要增加額外促銷或其他。我們看待這個業務時,會考量我們有各種產品以及推出的新產品、我們所做的變更。我們會透過促銷來推動出貨量並提升各區域的採用率。所以促銷會因地區而異,但沒有什麼異常。而且我們很高興看到 ASP 最終的表現,並且基於——考量到國際市場的正向成長、我們在青少年(teens)市場看到的正向成長,以及我們看到強勁的非綜合(noncomprehensive)成長——我們對此有良好預期。把這些都納入後,我們的 ASP 仍可維持持平。
Operator
Operator
Our next question comes from the line of Steve Beuchaw with Morgan Stanley.
我們下一個問題來自 Morgan Stanley 的 Steve Beuchaw。
Stephen Christopher Beuchaw - Equity Analyst
Stephen Christopher Beuchaw - Equity Analyst
I wanted to focus on how you thought about incorporating any potential contribution from the sales force additions in the outlook for 2019. If I think back to -- in past years where there had been substantial adds to the sales force, something like 6 months after those feet hit the street, we saw a benefit. So in 2019, are you modeling in any benefit from these rep adds that you made already? If so, can you give us a sense for how big those might be? And I'm just curious. As we think about the outlook for the year, let's call it 25% on volumes, 25%, 27% in the first quarter, it just doesn't look like there's any anticipation of acceleration or benefit from those hires.
我想聚焦在你們如何在2019年的展望中,納入新增銷售人力可能帶來的貢獻。如果我回想——過去幾年當銷售團隊有大幅增員時,大概在這些人員上線後約6個月,我們就看到效益。所以在2019年,你們是否在模型中納入你們已經新增的這些業務代表所帶來的任何效益?如果有,你能讓我們了解大概會有多大嗎?另外我也好奇。當我們看全年展望,假設出貨量成長約25%,第一季約25%、27%,看起來並沒有預期會因為這些招募而加速或受益。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, Steve. This is John. Yes, 6 months to 9 months is kind of the range you would expect to really start seeing those salespeople that you add once they're fully trained and have their territories and can kind of hit. So we should see an acceleration in the second half given the adds that we have. And as we see, we factored in into our guide as much as we can see now based on those adds.
是,Steve。我是 John。是的,6到9個月大概是你會預期開始真正看到你新增的那些業務人員帶來成果的時間範圍,因為他們需要完成訓練、分配好區域,然後才能開始發揮。所以考量到我們的增員,我們應該會在下半年看到加速。而就我們目前基於這些增員所能看到的部分,我們已盡可能把它納入我們的指引。
Stephen Christopher Beuchaw - Equity Analyst
Stephen Christopher Beuchaw - Equity Analyst
Okay. And then I would agree with the comment that was made earlier about where the paranoia is going to shift. And so I just wanted, given in part in response to the many e-mails I've gotten here in the last 45 minutes or so, give you a chance to just comment on your thinking on competition. Is there any sign of competition being relevant in the field that you can pick out at this point or still the view that it's just not material, not something that people ought to be thinking about?
好的。然後我同意先前提到的評論,關於「焦慮」將會轉移到哪裡。所以我想,部分也是回應我在過去45分鐘左右收到的許多電子郵件,給你一個機會談談你們對競爭的看法。到目前為止,在第一線是否有任何跡象顯示競爭已變得相關、你們能指出來的?還是仍然認為它不具實質性,不是大家需要去擔心的事情?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Steve, it's Joe. We -- obviously, we've seen Ormco down in ANZ, and I think we saw a recent announcement that they are going to kind of pace themselves as they go through 2019. I think you're seeing the same thing out of 3M, too. So honestly, Steve, we know you guys do surveys, and we read your surveys. We do our own or whatever. We know some of the docs out there are trying these product lines. And we have access to some of the software that's going on out there and the product lines that they're representing or whatever. But I don't want to -- I don't diminish it. But as far as 2019 goes, we're not thinking about any major competitive issues that we're going to face in any of our key areas or key geographies right now. We think this will take some time for them to ramp. We've talked about this before. This business is not easy. You have to be able to hit on a lot of cylinders. You got to have a good sales force that touches the customers and can make that doctor feel really strong about the product line. Secondly, you have to have really good treatment planning and consistent treatment planning that can deliver. And third, you got to have an operation organization that can deliver these things in sequence and on time and high quality. And putting those things together is difficult. And so 2019, we're not factoring in a huge amount of what we think is competitive pressure.
Steve,我是Joe。我們——顯然——已經看到Ormco在澳洲與紐西蘭(ANZ)市場走弱,而且我想我們也看到他們最近的公告,表示在2019年會在推進節奏上稍微放慢、按部就班。我認為你也在3M那邊看到同樣的情況。所以坦白說,Steve,我們知道你們會做調查,我們也會閱讀你們的調查。我們也會做自己的調查或其他方式。我們知道外面有些醫師正在試用這些產品線。而且我們也能接觸到市面上正在運作的一些軟體,以及他們所代表的產品線等等。但我不想——我不會輕忽這件事。不過就2019年而言,我們目前並不認為在任何關鍵領域或關鍵地理市場會面臨重大的競爭問題。我們認為他們需要一些時間才能拉升規模。我們之前談過這點。這門生意並不容易。你必須在很多環節都做到位。你得有一支優秀的銷售團隊能接觸客戶,並讓醫師對該產品線建立非常強的信心。第二,你必須有非常好的治療規劃,而且治療規劃要一致、可交付。第三,你必須有一個營運組織,能按順序、準時且高品質地交付這些東西。把這些要素整合在一起是困難的。因此在2019年,我們並未把我們認為的競爭壓力大量納入考量。
Operator
Operator
Our next question comes from the line of Erin Wright with Crédit Suisse.
我們的下一個問題來自Crédit Suisse的Erin Wright。
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
A couple of international ones here. I guess, can you speak to the dynamics in terms of fundamental demand trends in China given the broader macro dynamics? And could you also speak to the competitive landscape and how that's evolving there? And then also on Brazil, just as you build out that market, any sort of surprises there that you're seeing in the broader traction in Brazil?
這裡有幾個國際市場的問題。我想請你談談,在更廣泛的總體經濟環境影響下,中國的基本需求趨勢在動能上呈現什麼樣的變化?也請你談談當地的競爭格局,以及它如何演變。另外關於巴西,隨著你們持續拓展那個市場,你們在巴西整體的市場牽引力上是否看到任何意外或驚喜?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. Erin, it's Joe. From a China standpoint, look, our demand there has been great. I think as I talked about in my opening, it's a really underpenetrated marketplace. And so -- and there's a lot of demand for our product line. So our manufacturing investments we're making there, our treatment planning, all those things that make us a local company, we think will allow us to really penetrate that market at a higher rate. So look, I mean, we're not numb to the international scene right now, where people are concerned about China demand. We don't have anything to report right now that would say that we have a diminishing or a paranoia over China demand as we go into 2019. As far as competition over there, Erin, Angel Align is the most credible competitor that we have there. I would say that Angel has really focused on kind of Tier 3 cities in areas of China where we've really focused on in the first 5 years or so of our existence in China in Tier 1 or 2 cities, and we've moved into Tier 3. We don't feel that Angel is throttling our growth there at all. They are a fast follower. We see them in different areas that come after us. But we -- there's not a whole lot of head-to-head competition we feel right now, and I think that reflects not a whole lot about Angel being either good or bad. It just reflects the size of this marketplace and the investments you have to make in the sales force, how you really have to service that marketplace. There's a lot of work that you have to do. The channels just don't exist right now in the sense that you have to build those channels and really make them viable. So right now, we consider them a competitor and our largest competitor, I'd say, in the world, in the sense of a number of clear aligners that they supply. We don't look at them right now as slowing us down in China. And the Brazil surprise. I'd say that the surprise for all of us in Brazil is the incredible uptake of our product line there. You saw the 1,300 doctors that we've trained there recently. They're so excited about the product line. It's -- we talk about Spain often in the sense of the uptick of our product in Spain and the growth there. We see the same kind of enthusiasm and the same kind of, what I would call, Latin enthusiasm for what our product can do and really bring to that area. So we look to make major investments there in increasing our sales force and our presence in the Brazilian area. We really feel good about Brazil from a standpoint of future growth of our product line there.
是的。Erin,我是Joe。就中國而言,你看,我們在那裡的需求一直非常好。正如我在開場時提到的,那是一個滲透率非常低的市場。因此——對我們的產品線有很大的需求。所以我們在當地所做的製造投資、治療規劃,以及所有讓我們更像一家在地公司的事情,我們認為將使我們能以更高的速度深入滲透該市場。所以你看,我的意思是,我們並非對目前的國際情勢毫無感覺,市場上確實有人擔心中國需求。但目前我們沒有任何可報告的跡象顯示,當我們進入2019年時,中國需求正在減弱,或我們對中國需求產生疑慮。至於那邊的競爭,Erin,Angel Align是我們在當地最具可信度的競爭對手。我會說,Angel主要聚焦在中國的三線城市;而我們在進入中國市場的前5年左右,主要聚焦在一、二線城市,之後我們也已經往三線城市擴展。我們不覺得Angel在那裡對我們的成長造成任何抑制。他們屬於快速跟進者。我們在不同區域看到他們跟在我們後面進入。但我們——目前並不覺得有太多正面交鋒式的競爭;我認為這並不太反映Angel本身是好是壞。這更多反映了市場規模,以及你必須在銷售團隊上投入多少資源、你必須如何真正服務這個市場。你需要做大量工作。就通路而言,目前並不存在現成的通路;你必須建立通路並讓它真正可行。因此目前我們把他們視為競爭對手,而且我會說,就他們供應的透明牙套數量而言,他們是我們在全球最大的競爭對手。但我們目前不認為他們在中國拖慢了我們。至於巴西的驚喜。我會說,對我們所有人而言,巴西的驚喜在於我們產品線在那裡的採用速度非常驚人。你們看到我們最近在那裡培訓了1,300位醫師。他們對這條產品線非常興奮。我們常提到西班牙,因為我們產品在西班牙的採用提升與成長。我們在巴西也看到同樣的熱情,以及我所稱的拉丁式熱情——對於我們的產品能做什麼、能為那個地區帶來什麼。因此我們希望在那裡進行重大投資,增加我們的銷售團隊與在巴西地區的布局。從我們產品線未來成長的角度來看,我們對巴西非常有信心。
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Okay. Great. And a broader question on promotional activity. I'm just curious kind of what other promotional activity could you implement that isn't necessarily price-driven, whether it be comarketing arrangements or other types of incentives. Is this something that is in your game plan for 2019 or something that you're planning?
好的。很好。再問一個更廣泛的促銷活動問題。我只是好奇,你們還能實施哪些不一定由價格驅動的促銷活動,例如共同市場推廣(comarketing)安排或其他類型的激勵措施。這是否在你們2019年的計畫中,或是你們正在規劃的事情?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Erin, there's no lack of creativity in our commercial forces as promotions go, so there's a lot of adult supervision that we have to supply as we do those things. And what -- look at our ADAPT program as a good one. That's a program where we're trying to take doctors to 80% Invisalign and really demonstrate, as I mentioned in my opening, is that when you get to a digital practice, when you get to 80%, first of all, no one goes back, no one goes back to wires and brackets. You really set a precedent that you have control over your practice. You don't have 30% of your cases resulting in emergencies. Doctors aren't spending 45 minutes a day with patients. It's just a much -- but you have to get to 80% to make that work. We'll continue to put money into that. That's not like a promotional program that we would offer at a lower price. That's just a program we work with docs who really want to get there. There's always promotional programs that we do that we offer aligners to staff at orthos that are starting up with us or also with GPs or whatever so that they can understand the product and have that experience and be able to communicate that well to patients. They come into the practice. Those are ongoing promotions that we do in all 3 geographies, too. We do have seasonal promotions at times in different countries and different areas. But I'd say that we have a -- this is outside of the third quarter issue obviously we reported on kind of ad nauseam over the last 6 months. We have a good handle right now on what promotions that we'll offer throughout the year.
Erin,就促銷而言,我們的商業團隊並不缺乏創意,所以在做這些事情時,我們必須提供相當多的管理與監督。而且——你可以把我們的ADAPT計畫視為一個很好的例子。那是一個我們試圖把醫師帶到80% Invisalign占比的計畫,並真正證明——如我在開場提到的——當你進入數位化診所、當你達到80%時,首先,沒有人會回頭,沒有人會回到傳統鋼絲與托槽。你確實建立了一個先例:你能掌控你的診所。你不會有30%的病例最後變成急診狀況。醫師也不需要每天花45分鐘處理病患。整體會——但你必須達到80%才能讓這件事奏效。我們會持續投入資金在這上面。那不像是我們會用更低價格提供的促銷方案。那只是我們與真正想達到那個目標的醫師一起合作的計畫。我們也一直有一些促銷方案,例如提供牙套給剛開始與我們合作的矯正科診所的員工,或是給一般牙醫(GPs)等,讓他們能理解產品、親身體驗,並能更好地向病患溝通。他們會進入診所。這些也是我們在三大地理區域都持續進行的促銷活動。我們也會在不同國家與不同地區於特定季節推出促銷。但我會說——這當然不包含我們在過去6個月已經反覆(幾乎到令人厭煩的程度)提到的第三季事件——我們目前對於全年將提供哪些促銷方案已有良好的掌握。
Operator
Operator
Our next question comes from the line of Ravi Misra with Berenberg Capital Markets.
我們的下一個問題來自 Berenberg Capital Markets 的 Ravi Misra。
Ravi Misra - Analyst
Ravi Misra - Analyst
So I wanted to get into the kind of the gross margin outlook in the commentary that you were providing. Can you help us understand maybe what the pushes and takes are between the 1Q guidance and kind of the 4Q guidance ramp? And especially in terms of what's that fixed overhead that's strapped there, kind of in the ball park? Is that somewhere around $10 million, $15 million a quarter right now that's annualized into your COGS on that that's going to fall off once the China sales ramp?
我想深入談談您在評論中提到的毛利率展望。您能否協助我們理解,第一季指引與第四季指引上調之間,可能有哪些拉抬與抵銷的因素?特別是就那部分被綁在裡面的固定間接費用而言,大概在什麼範圍?目前是否大約每季 1,000 萬到 1,500 萬美元,年化後計入你們的 COGS,並且在中國銷售放量後就會消失?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. Ravi, it's John. It's not that high. But when we think of our operation that we've had to date, really it's been a -- it's treatment planning in Costa Rica, and it's been manufacturing in Mexico. We are now -- as we've been expanding our treatment planning and now expanding out to China manufacturing, it's -- we want volume. We want to better push volume through those centers and get as much productivity as possible. So as we see some of the volume in -- the margin impact in the fourth quarter, that continues a bit into the fourth quarter. But as that volume comes through and as you don't have to add as much overhead, you see more and more productivity to be able to come through those whether treatment planning or the China manufacturing. And so we expect to see this kind of quarter-over-quarter of improvement through 2019 as we get more and more productive at these facilities.
是的。Ravi,我是 John。沒有那麼高。但當我們回頭看截至目前的營運,基本上是——在哥斯大黎加做治療計畫,並在墨西哥製造。現在——隨著我們擴大治療計畫的規模,並且進一步擴展到中國製造——我們需要的是量。我們希望讓更多產量通過這些中心,並盡可能提高生產力。因此,當我們在第四季看到一些量帶來的毛利影響時,這種影響會在第四季持續一段時間。但隨著產量進來、且你不必再增加那麼多間接費用,你會看到越來越多的生產力得以釋放,不論是在治療計畫端或中國製造端。因此,我們預期 2019 年會看到這種逐季改善,因為我們在這些設施的生產力會越來越高。
Ravi Misra - Analyst
Ravi Misra - Analyst
So it sounds like that's really going to be led by a step-up in the clear aligner gross margin versus the scanners?
所以聽起來,這主要會由透明牙套的毛利率提升來帶動,而不是掃描器?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, definitely. When you look at kind of where we're seeing that volume leverage as we expand out globally, it'll be on the clear aligners side, and we should see that progress through the year.
是的,絕對如此。當你看我們在全球擴張時所看到的量的槓桿效益,會是在透明牙套這一端,我們應該會在全年看到這方面的進展。
Ravi Misra - Analyst
Ravi Misra - Analyst
Great. And then maybe just 2 more questions. Just on the -- one on the orthodontics and then another kind of just on the consultations through the Invisalign brand experience. So just on these orthodontics step-down. I'm curious. That's the first time in, gosh, I think about 12, 14 quarters. I've seen that number stepped down. Any kind of impact -- I know you're saying that the impact from Ormco. 3M was kind of limited. But how about some of the other direct-to-consumer manufacturers there? Is that playing into that at all? And in the sense that, that end-user volume might actually be going down? And then second, you talk about the 85 -- I think the 85,000 people that have visited the store and gotten a consult. What's the conversion rate on that? Are those getting scans to actually becoming consumers of your product?
很好。那我再問兩個問題。一個是關於矯正業務,另一個是關於透過 Invisalign 品牌體驗所進行的諮詢。先談矯正業務的下滑。我很好奇。這是我第一次在——天啊,我想大概 12、14 個季度——看到這個數字下來。我看到這個數字出現下滑。有任何影響嗎——我知道你們說 Ormco、3M 的影響相對有限。但其他一些直接面向消費者(DTC)的製造商呢?這是否也有影響?也就是說,終端使用者的量可能真的在下降?第二,你提到有 85——我想是 85,000 人到店並接受諮詢。那個轉換率是多少?這些人有去做掃描,最後真的成為你們產品的消費者嗎?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Ravi, Joe again. From a standpoint of Americas and orthodontics standpoint, again, I'll tell you we had our second best year in history following from the standpoint of overall orthodontic growth. When you talk about SDC, my feeling on SDC is they don't really take orthodontic cases. Remember, the normal orthodontist in the United States is 75% to 80% teen. You won't see many teens being done by SDC, and so those cases would primarily come out of GPs. Adults, kind of simple cases that are going on. As I mentioned, we had our highest GP sales rate ever in North America in 2018. So neither of those dimensions do I think that we have our experience competition enthralling the business in some way whether or will affect us in 2019. As far as the Invisalign stores and the scan ratios, all those things, look, we just -- we're still working through these [12]. We haven't released that information from an overall standpoint yet, and at some point in time when we think we're ready and we really have that ironed out. And I'd say that, Ravi, not that we're hiding anything. It's just we found that when you look at CCAs, we call it clear order in this business, this can take anywhere from 4 to 6 months to 7 months to really iron itself out. We see patients go in and get scanned. And then there's this huge halo effect because when we do this local advertising, that benefits not just the doctors in the program but also in a broader sense, any doctor that's within that 10-mile or 15-mile range. So when we're really -- when we're ready to report this, we'll report it in a broad sense to that halo effect, the whole, what you talked about, the conversion rate and also what that means from a timing standpoint, okay?
Ravi,我是 Joe,再回答一次。就美洲地區與矯正業務的角度來看,我再說一次:從整體矯正成長的角度,我們剛完成了史上第二好的年度表現。談到 SDC,我對 SDC 的看法是,他們其實不太接矯正病例。請記得,美國一般矯正醫師的患者結構有 75% 到 80% 是青少年。你不會看到很多青少年由 SDC 來做,因此那些病例主要會來自一般牙醫(GP)。成人方面,則是一些相對簡單的病例。如我提到的,我們在 2018 年北美的 GP 銷售成長率創下歷史新高。所以在這兩個面向上,我不認為我們的經驗顯示競爭在某種程度上正在侵蝕業務,或會在 2019 年影響我們。至於 Invisalign 門市與掃描比率等所有這些事情,坦白說,我們還在處理這些 [12]。我們目前還沒有從整體角度對外發布這些資訊;等到某個時間點,我們覺得準備好了、也真的把它釐清之後,才會公布。我想說的是,Ravi,我們不是在隱瞞什麼。只是我們發現,當你看 CCAs——在這個業務裡我們稱之為 clear order——這可能需要 4 到 6 個月、甚至 7 個月,才能真正把流程磨合到位。我們看到病患進來做掃描。然後會有很大的光環效應(halo effect),因為我們做的在地廣告,不只讓計畫內的醫師受益,也更廣泛地讓 10 英里或 15 英里範圍內的任何醫師受益。所以當我們真的——當我們準備好要報告時,我們會以更廣泛的方式把光環效應整體納入來報告,包括你提到的轉換率,以及從時間節奏角度來看這代表什麼,好嗎?
Operator
Operator
Our next question comes from the line of John Kreger with William Blair.
我們的下一個問題來自 William Blair 的 John Kreger。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Joe, a few times on the call, I think you talked about your view that it's sort of critical to get your customers to really make the digital conversion of their practices. Can you just talk a bit more about what that really means? And is that an expense on your part? Obviously, it's got some positive implications for volumes if and when it happens. But what are the sort of practical implications of getting an ortho practice to make that transition?
Joe,在這通電話中你提到好幾次,你認為讓客戶真正完成其診所的數位化轉換是相當關鍵的。你能否再多談一點這實際上代表什麼?這會是你們這邊的費用嗎?顯然,如果以及當它發生時,對量會有一些正面意涵。但讓一家矯正診所完成那個轉換,在實務上會有哪些影響?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
John, that's a good question. There's 3 key parameters, right, is first of all, there's extended payment terms that you have to deal with. Because when you go with a clear aligner product versus wires and brackets, their cost overall are about 4x from a variable cost standpoint of which you'd have with wires and brackets. So you just have to get ready for that cash play and try in some way to extend them those kinds of payments. Secondly, you have to look at their workflows. Because when you really go to a full digital practice, it changes completely really. We find out in our ADAPT program that you need fewer chairs but you'd need more consultation rooms to put people in, to show them simulations, to talk them through what it would be. With no emergency cases, it completely redefines in the sense of how a day goes in a doctor's office. It's not 30% of the time are people scrambling around trying to find someone that can fix something that occurred with the wires and brackets in some way. And then third is a demand component, is you're going to have to drive more demand within that practice, which Invisalign does. And so obviously, with $100 million spend that we do a year in attracting patients and moving them into doctors, how we pipe those patients into doctors, how they prepare themselves for both teens and adults to do that. So it's on those 3 dimensions. And John, specifically on the ADAPT program, we're just going through that program right now and how we'll offer that to customers and what it will cost to actually do that to customers at that point. And after we've done probably 5 to 8 of these and have them complete, we'll have a better story in the sense of -- a more complete story in the sense of here is how we'll do it, what those costs will be. But don't look at those as being overly broad. Remember, we have iPro today that we basically use to take customers through clinical kind of episodes. So we have our concierge service that grabs patients to move them through doctors, too. So the big components of operations that you need to work around the ADAPT, we have those in place. We just have to modify them more for this 80% or digital treatment play.
John,這是個好問題。有3個關鍵參數,對吧,首先,你必須面對延長的付款條件。因為當你採用透明牙套產品而不是鋼絲與托槽時,從變動成本的角度來看,其整體成本大約是鋼絲與托槽的4倍。所以你必須為那樣的現金流安排做好準備,並想辦法在某種程度上把這類付款期限拉長。第二,你必須檢視他們的工作流程。因為當你真正轉向全數位化診所時,整體會完全改變。我們在ADAPT計畫中發現,你需要更少的診療椅,但需要更多的諮詢室來安排病人,向他們展示模擬結果,並帶他們了解會是什麼樣子。在沒有急診案例的情況下,這會徹底重新定義醫師診所一天的運作方式。不再是有30%的時間,大家手忙腳亂地想找人去處理某些因鋼絲與托槽而發生的問題。第三是需求面,你必須在該診所內帶動更多需求,而Invisalign確實能做到。因此很明顯,憑藉我們每年投入1億美元來吸引病患並把他們導入醫師端的支出,我們如何把這些病患導入醫師、以及醫師如何為青少年與成人做好準備來承接這些病患。所以就是這3個面向。而John,特別就ADAPT計畫而言,我們現在正走過這個計畫,並在評估我們將如何提供給客戶,以及到那個時點實際向客戶收取多少費用。在我們大概完成5到8個案例之後,我們會有更好的說法——也就是更完整的說法——來說明我們會如何執行、成本會是多少。但不要把這些看得過於寬泛。記住,我們今天有iPro,基本上用來帶客戶走過臨床類型的流程。所以我們也有禮賓服務,去抓取病患並把他們導入醫師端。因此,圍繞ADAPT你需要調整的營運大項,我們都已經具備。我們只是需要針對這個80%或數位治療的策略,把它們再做更多調整。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Very helpful. One quick one, John. As you think about the '19 outlook that you described for us, what sort of number of stores does that envision by year-end?
非常有幫助。John,再快速問一個。就你為我們描述的2019年展望來看,年底預計會有多少家門市?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, we have 12 as we noted now. It's really not a material change from that. We're evaluating what's best locations, what makes sense for us. But we really want to drive productivity and conversion at the stores we have before we go on a larger scale.
是的,如我們剛才提到的,我們目前有12家。基本上不會有實質性的變化。我們正在評估哪些地點最好、哪些對我們有意義。但在我們更大規模擴張之前,我們真的想先提升現有門市的生產力與轉換率。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Okay. So we shouldn't expect that to be materially different by December of '19?
好的。所以到2019年12月,我們不應該預期會有實質不同?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
That's correct.
沒錯。
Operator
Operator
Our next question comes from the line of Steven Valiquette with Barclays.
下一個問題來自Barclays的Steven Valiquette。
Steven J. James Valiquette - Research Analyst
Steven J. James Valiquette - Research Analyst
So I guess just given the ramp in investments in 2019, with likely some slower EPS growth. I kind of feel that 2019 is maybe somewhat similar to what Align went through back in 2015, where that was, let's call it, somewhat of a throwaway year for earnings growth because of heavy spending. But then the company came out of that and really had 3 strong years of growth in 2016 through 2018. I know it's a different management team back in 2015. But should we draw really any sort of parallels for 2019 where maybe you're just setting yourself up for another strong earnings growth cycle in the next couple of years beyond 2019 with the investments that you're making this year?
所以我想,考量到2019年投資的加速,EPS成長可能會較慢。我有點覺得2019年可能有點像Align在2015年經歷的情況,當時因為大量支出,姑且稱之為在獲利成長上算是「放掉的一年」。但公司之後走出來,在2016到2018年有3年很強勁的成長。我知道2015年的管理團隊不同。但我們是否應該在2019年做任何類似的類比:也就是說,你們今年的投資,可能是在為2019年之後接下來幾年另一個強勁的獲利成長循環做準備?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Steve, it's Joe. I think first of all, I feel we play offense in this business. So even though we talk about restructuring or if we talk about adding salespeople, when we talk about defending our IP, all of those things are, to me, setting a foundation for future growth in the business. When you sit back and you look at this business, we're incredibly underpenetrated based on consumer preference for clear aligners to move teeth and also the size of the market that digital opens up even beyond, the 12 million orthodontic case starts that we talk about globally. So please don't call 2019 a throwaway year. Hopefully, the earnings and the growth that we're projecting here are substantial. And we haven't even mentioned the law of large number on you guys over the last 3 years, right? Because we continue to build these huge percentages over top incredibly larger numbers than what we had previously. So I look at this as -- don't -- look at it as these are aggressive investments in a young business to lay a foundation to allow us to be better in the future. And that's -- we have to take these.
Steve,我是Joe。我想首先,我覺得我們在這個業務上是採取進攻策略。所以即便我們談重組、或談增加業務人員、或談捍衛我們的智慧財產權,對我而言,這些都是在為未來的業務成長打下基礎。當你退一步看這個業務,基於消費者偏好用透明牙套來移動牙齒,以及數位化所開啟的市場規模甚至超越我們全球所談的1,200萬個正畸起始病例,我們的滲透率仍然非常低。所以請不要把2019年稱作「放掉的一年」。希望我們在這裡所預測的獲利與成長是相當可觀的。而且我們甚至還沒提到你們在過去3年所面臨的「大數法則」,對吧?因為我們持續在比以往大得多的基數之上,建立這些很高的百分比成長。所以我看待這件事是——不要——把它看成是浪費;而是把它看成在一個仍然年輕的業務中進行積極投資,以奠定基礎,讓我們未來能做得更好。而這些——我們必須去做。
Steven J. James Valiquette - Research Analyst
Steven J. James Valiquette - Research Analyst
Yes. I guess a quick follow-up to that, would just be how important is consistent EPS growth at Align at this stage of the corporate life cycle? Or is this still mainly about driving top line growth for all the things that you just mentioned?
是的。我想快速追問一下,在公司生命週期的這個階段,對Align而言,維持EPS的持續成長有多重要?或者這仍主要是關於推動營收成長,也就是你剛才提到的那些事情?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Steve, this is John. It's both. I mean, we want to drive top line. We want to be able to grow this business. As Joe mentioned, we're vastly underpenetrated, and we have products and technology to be able to increase that market. But at the same time, we want to be able to grow profitably. And as we layer on some of these investments, we expect -- whether it's China or sales force addition or others that we're adding in, over time, we'll be able to see those benefits. And that over time, as we laid out, is over 2019. We should see that sequential improvement quarter-over-quarter as those investments start to pay off as we move forward. But we want to make sure that we're returning the most back to our shareholders, and that comes from revenue growth and the volume that we drive as well as doing this from a profitability standpoint. And we're very aware of the long-term growth model, and we stick with that.
Steve,我是John。兩者都重要。我的意思是,我們想推動營收。我們希望能夠讓這個業務成長。如Joe所提,我們的滲透率仍然非常低,而我們有產品與技術能夠擴大那個市場。但同時,我們也希望能夠在獲利的前提下成長。而當我們逐步加上這些投資——不論是中國、擴增銷售團隊或其他我們正在增加的項目——隨著時間推進,我們將能看到這些效益。而我們所說的「隨著時間推進」,就是在2019年期間。隨著這些投資開始產生回報、我們往前推進,我們應該會看到逐季的改善、也就是每一季相較上一季的改善。但我們要確保能為股東帶來最大的回報,而這來自於營收成長與我們所帶動的量,同時也來自於以獲利的角度來做這件事。而我們非常清楚長期成長模型,並會持續遵循它。
Operator
Operator
Our next question will come from the line of Richard Newitter with SVB-Leerink.
下一個問題將來自SVB-Leerink的Richard Newitter。
Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst
Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst
Joe, I was just wondering -- I know you guys are still -- it's still really, really early days in China, and the opportunities are enormous, including your growth rate in that region, haven't really shown any slowdown. But can you just talk a little bit about what -- we've seen some headlines and some other companies talking about the macro slowdown in China in the consumer discretionary realm. Can you give us your thoughts from the way you see things? Clearly, you're investing, so I would imagine there's nothing there that would suggest there's any slowing growth. But what are you seeing kind of at the ground level in terms of the macro?
Joe,我只是想問——我知道你們在中國仍然——仍然是非常非常早期的階段,而且機會非常巨大,包括你們在該地區的成長率,也還沒有顯示任何放緩。但你能否稍微談談——我們看到一些新聞標題,以及一些其他公司在可選消費領域談到中國宏觀放緩。你能從你們的觀察角度談談你的看法嗎?顯然你們正在投資,所以我想像不出有任何跡象顯示成長在放慢。但就宏觀層面而言,你們在第一線看到的是什麼?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I mean, we -- like I mentioned before, Richard, this is -- the growth that we saw throughout 2018 was really strong in China. I mean, obviously, we're making these investments in China. It's a commitment. They are our second largest country in the world right now. The underpenetration, the opportunity there is huge. Look, I mean, we're up with global events. We see the issues going on with China and United States. And hopefully, they'll come to a trade deal sooner or later. I look at that investment. When I talked about manufacturing there, it is moving closer and having a Chinese business and being able to operate in that country with a lot of fluidity. But it also makes me feel good that we have a good insurance policy in the sense of the trade dynamics between the 2 countries, too. So right now, again, we haven't seen what other companies are reporting. I think the penetration piece we're talking about is probably maybe the variable of difference between the 2. We're not saying that we're recession-proof ever. I think that's a ridiculous position to take. But what we've seen right now in the growth rates and what we've been experiencing, right now, we're looking for a good 2019 in China.
我的意思是,我們——如我先前提到的,Richard,這是——我們在 2018 年於中國看到的成長非常強勁。我的意思是,很明顯地,我們正在中國進行這些投資。這是一項承諾。他們目前是我們在全球第二大的國家市場。滲透率仍偏低,那裡的機會非常巨大。你看,我的意思是,我們也關注全球事件。我們看到中美之間正在發生的問題。也希望他們遲早能達成貿易協議。我看待那項投資。當我談到在那裡製造時,這代表把生產移得更近,並擁有一個中國業務,能夠在該國以很高的靈活性運營。但同時,從兩國之間貿易動態的角度來看,這也讓我覺得我們有一份很好的保險政策。所以目前,再次強調,我們還沒看到其他公司在報告什麼。我認為我們所談的滲透率因素,可能就是兩者之間差異的變數。我們並不是說我們永遠不會受衰退影響。我覺得那是個荒謬的立場。但就目前我們看到的成長率以及我們正在經歷的情況而言,現在我們期待 2019 年在中國會有不錯的表現。
Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst
Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst
Excellent. And just if you could maybe just -- maybe you mentioned it earlier, mandibular advancement. What's contemplated? Or how are you thinking about the contribution in 2019? Should we think of that launch kind of hitting the ground running right off the bat? Is that more of a gradual cadence? And what's contemplated in the outlook?
很好。另外,如果你可以再談一下——也許你先前提過——下顎前移(mandibular advancement)。目前的規劃是什麼?或者你們如何看待它在 2019 年的貢獻?我們是否應該把這次上市視為一開始就能迅速起量?還是會是較為循序漸進的節奏?在展望中是如何規劃的?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I'll take a high level and let John, take the specific level. But remember, MAF was just approved in November of 2018. As [this year] -- I expect our normal uptake in the United States, which is -- orthos will do 2 or 3 cases and get used to it. It's a phenomenal product. It really is. To think you straighten your teeth. It can move your mandible forward in that sense and build bone. It's just -- it's incredible. But when it's something that big and that revolutionary, doctors -- orthos are conservative anyway. And obviously, they're going to take their time in the sense of proving it. Now (inaudible) MAF has been outside the United States for a while, too. So we have, I think, 17,000 cases we talked about that we've gone through it. What's really interesting, too, is we have several updates from [Jelco] and the engineering team on MAF also. When teeth are shorter, how you arrange the aligners to make it work, making sure the wings are a lot stronger than before. So as this is approved in the United States. We think we've significantly improved the product over the last 12 months, too. Now we find, too, is just the great halo effect around MAF and Teen. If you start to do more MAF, you do more Teen. And so we're looking forward to that. But again, it's new days in the United States, and we'll give you updates as we go through the year.
我先從高層次回答,然後讓 John 來談具體細節。但請記得,MAF 是在 2018 年 11 月才剛獲得核准。在[今年]——我預期在美國會有我們一般的採用曲線,也就是——矯正醫師會先做 2 或 3 個案例,熟悉之後再逐步增加。這是一個非常出色的產品。確實如此。想像你在把牙齒排整齊的同時,它還能在那個意義上把下顎往前移並促進骨生成。這真的——令人難以置信。但當它是如此重大且具革命性的產品時,醫師——矯正醫師本來就比較保守。而且很明顯地,他們會花時間去驗證它。另外(聽不清),MAF 在美國以外也已經有一段時間了。所以我們有——我想我們提過大約 17,000 個案例已經使用過。另外很有意思的是,我們也從 [Jelco] 與工程團隊那裡拿到 MAF 的幾項更新。例如當牙齒較短時,如何安排隱形牙套讓它能運作,以及確保翼片比以前更堅固。因此,隨著它在美國獲准。我們認為在過去 12 個月裡,我們也大幅改良了產品。我們也看到,MAF 與 Teen 周邊有很強的光環效應。如果你開始做更多 MAF,你也會做更多 Teen。所以我們很期待這一點。但再次強調,在美國這仍是新開始,我們會在今年進行過程中持續向各位更新。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
And so when we look at our forecast and we think about flat ASPs, this is one that helps us. This is a positive move back to our ASPs because it's a full case, it's a teen case, it's complicated. Like Joe said, it gives us more and more teen volume, and we look at that as favorable mix and favorable growth for us.
因此,當我們看我們的預測並考量 ASP 持平時,這是其中一項能幫助我們的因素。這會對我們的 ASP 帶來正向推動,因為它是完整療程、是青少年案例,而且更複雜。如 Joe 所說,它會帶來更多的青少年量,我們將其視為對我們有利的產品組合與有利的成長。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Okay. Well, thank you, everyone, for joining us on the call today. We look forward to catching up with you at subsequent conferences. And if you have any questions, please contact Investor Relations. Have a great day.
好的。那麼,感謝各位今天參與電話會議。我們期待在後續的會議上再與各位交流。若有任何問題,請聯絡投資人關係部門。祝各位有美好的一天。
Operator
Operator
Thank you. This concludes today's conference. You may disconnect your lines at this time, and thank you for your participation.
謝謝。今天的會議到此結束。您現在可以掛斷電話線,並感謝您的參與。